Meta-analysis strategies for heterogeneous studies in genome-wide association studies by Hong, Jaeyoung
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Meta-analysis strategies for
heterogeneous studies in
genome-wide association studies
https://hdl.handle.net/2144/17065
Boston University
BOSTON UNIVERSITY 
 
GRADUATE SCHOOL OF ARTS AND SCIENCES 
 
 
 
 
 
Dissertation 
 
 
 
 
META-ANALYSIS STRATEGIES FOR HETEROGENEOUS STUDIES IN 
GENOME-WIDE ASSOCIATION STUDIES 
 
 
 
by 
 
 
 
 
JAEYOUNG HONG 
 
B.S., Koomin University, 2002 
M.S., University of Illinois at Chicago, 2011 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2016  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©  2016 
 JAEYOUNG HONG 
 All rights reserved  
Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 Ching-Ti Liu, Ph.D. 
 Associate Professor of Biostatistics 
 
 
Second Reader _________________________________________________________ 
 Josée Dupuis, Ph.D. 
 Professor of Biostatistics 
 
 
Third Reader _________________________________________________________ 
 Kathryn L. Lunetta, Ph.D. 
 Professor of Biostatistics 
  
 
  
 iv 
 
ACKNOWLEDGMENTS 
 
I would like to acknowledge my parents, Sung-gi Hong and Eul-sun Park, for their 
encouragement and support throughout my life journey. I thank my grandmother, Kyung-
suk Lee, for her unlimited love. I also thank my brother, Keung-young Hong, for his 
support and friendship.  
 
It has been a long educational journey towards this degree. First of all, I would like to 
thank my advisor Dr. Ching-Ti Liu for his guidance and encouragement in my 
dissertation research. This dissertation would not be completed without his expertise and 
guidance. I would like to thank my committee members, Dr. Josée Dupuis, Dr. Kathryn 
Lunetta, Dr. L Adrienne Cupples, and Michael Lavalley, for sharing their insightful 
discussions and statistical expertise. 
 
I would like to thank my lovely wife, Lani Hong, for her devoted support and love. I 
thank my children, Elizabeth, Noah and Emily Hong, for their bottomless healthy energy 
and inspiration. 
 
 
  
 v 
 
META-ANALYSIS STRATEGIES FOR HETEROGENEOUS STUDIES IN 
GENOME-WIDE ASSOCIATION STUDIES 
 
JAEYOUNG HONG 
Boston University Graduate School of Arts and Sciences, 2016 
Major Professor: Ching-Ti Liu, Associate Professor of Biostatistics 
 
ABSTRACT 
 
Meta-analysis is a statistical technique that combines results from multiple independent 
studies to make inferences about parameters of interest. Although it is popular for 
parameter estimation and hypothesis testing, meta-analytic approaches that incorporate 
heterogeneous studies have not been fully developed. For heterogeneous studies, we do 
not expect all of the studies to have the same true underlying effect and the use of the 
fixed-effects model in a meta-analysis in this situation violates the assumption of 
homogeneity of effect size. Heterogeneity among studies can arise from multiple sources 
such as differences in populations by ancestry, differences in study designs, and different 
impacts of environmental exposures on the effect of the variable of interest. In this thesis, 
we introduce an analytic strategy and statistical models for meta-analysis of potentially 
heterogeneous studies. First, we propose a two-stage clustering approach to account for 
heterogeneity in trans-ethnic meta-analysis of genome-wide association studies (GWAS). 
Specifically, we cluster studies in the two-stage approach using cohort-specific genetic 
 vi 
 
information prior to meta-analysis to account for between-cluster heterogeneity as well as 
to bolster within-cluster homogeneity. An extensive simulation study shows that this 
approach improves power and diminishes computational intensity compared to existing 
methods for trans-ethnic meta-analysis. Next, under a meta-regression framework, we 
develop a likelihood ratio test (LRT) statistic to accommodate multiple random effects. 
We allow multiple sources of heterogeneity in terms of study characteristics and model 
the heterogeneities as random effects. We show that the proposed LRT maintains a 
similar or higher power than other existing methods in a simulation study especially 
when heterogeneity exists. We apply this new approach to meta-analyze genome-wide 
association data. Lastly, we derive a score test in the same context as our proposed new 
LRT and show the substantial advantage of the score test in computational efficiency 
compared to the new LRT. The introduced strategy and methodologies can effectively 
and efficiently aggregate the evidence from potentially heterogeneous studies in 
statistical genetics and other research areas.  
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Chapter 1 Introduction 
 
1.1 Genetic Association Studies 
In genetic association studies, investigators are interested in testing the association of 
genetic determinants with complex human disease or disease-related traits. Usually, 
biallelic common variants, defined as genetic variants with minor allele frequency (MAF) 
greater than 5% or 1%, are examined in genome-wide association studies (GWAS). 
Depending on whether the trait is quantitative or qualitative, linear or logistic regression 
models are used to test the genetic association adjusting for study covariates. For 
correlated data, mixed effects or generalized estimating equation models may be used. 
 
In recent years, large numbers of genetic variants have been associated with complex 
diseases and disease-related traits using GWAS and candidate gene studies. Despite this 
success, the effect sizes of identified genetic variants are small, and they only explain a 
small proportion of the heritability of complex disease or disease-related traits. Thus, a 
large number of samples are needed and an analysis in any single study is usually under-
powered to detect weaker signals. The variants with weaker associations can be identified 
with increased power by increased sample size (McCarthy et al. 2008; Manolio et al. 
2009). Therefore, investigators combine summary statistics of the individual studies and 
meta-analyze them to detect those weaker signals with better power. This meta-analysis 
approach increases power by boosting sample size and has been shown to be as efficient 
as combining individual participant data under most conditions (Lin and Zeng 2010). 
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Thus, the meta-analysis approach is an effective and more practical way to explore those 
weaker signals. 
 
Although meta-analysis has been widely used for GWAS, it has often been restricted to a 
single ancestral population. Because genetic architectures are different across diverse 
populations, investigators do not want to violate the homogeneity of effects assumption 
of the fixed effects (FE) meta-analysis model. However, properly meta-analyzing over 
diverse population studies would further increase sample size and could lead to higher 
power to detect novel genetic loci (Y. Li and Keating 2014). Also, leveraging linkage 
disequilibrium (LD) information across difference ancestral populations could enhance 
the ability of fine-mapping to detect functional genetic variants (Liu et al. 2012; Liu et al. 
2014; Boerwinkle and Heckbert 2014; Franceschini et al. 2012; Y. Li and Keating 2014).  
 
Most complex traits are influenced by not only the genetic determinants but also 
environmental factors. Epidemiology studies show the association of environmental 
variables with complex traits. Thus, it is reasonable to explore the interaction of genetic 
determinants and environmental variables to find additional genetic contributors and to 
explain some of the unexplained heritability. Another potential source of the unexplained 
heritability may be due to rare variants, defined by variants with MAF less than 1%. 
Some studies suggest that genes with common variants with modest effect sizes on 
complex disease may have rare variants with larger effect size (Manolio et al. 2009). 
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With decreasing cost and rapid advances of sequencing technology, rare variant analysis 
is now available and provides opportunity in explaining the “missing heritability”.  
 
1.2 Meta-Analysis  
Meta-analysis is used to combine results from multiple independent studies to make 
inferences about a parameter of interest. In general, meta-analysis methods apply p-value 
based approaches and effect-size based approaches. Among the p-value based 
approaches, Fisher’s method (Fisher 1925) combines p-values from all participating 
studies into a pooled test statistic as  
𝜒2𝐾
2 = −2∑ln (
𝐾
𝑖=1
𝑝𝑖) , 
where 𝐾 is a number of studies and 𝑝𝑖 is the p-value for testing the null hypothesis of no 
effect in the 𝑖𝑡ℎ  study. Under the null hypothesis of no effect, the test statistic follows a 
Chi-square distribution with 2𝐾 degrees of freedom. Another approach is the inverse 
normal method, independently suggested by Stoufer et al. (Stouffer et al. 1949) and 
Liptak (Liptak 1958). It converts p-values using a probit function to Z-scores and 
combines the transformed Z-scores into a pooled test statistic. The probit function is the 
inverse of the standard normal cumulative distribution function and converts uniformly 
distributed values to normally distributed values. The test statistic is 
Z1 = ∑
𝑧𝑖
√𝐾
𝐾
𝑖=1
 , 
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where 𝑧𝑖 = Φ
−1(
𝑝𝑖
2
) and Φ−1 is the probit function. The test statistic, Z1, follows a 
standard normal distribution under the null hypothesis of no effect. Two weighted inverse 
normal methods are proposed by Mosteller et al. (Mosteller, Bush, and Green 1954) and 
Liptak (Liptak 1958). Mosteller’s weighted inverse normal method involves a 
nonnegative weights to the test statistic. However, the Mosteller’s method as well as the 
two aforementioned methods do not take into account the sign of the effects. Liptak’s 
weighted inverse normal method (implemented in METAL software (Willer, Li, and 
Abecasis 2010)) incorporates the sign of the effect and accounts for study sample sizes. 
The test statistic is 
Z2 =
∑ 𝑤𝑖 𝑧𝑖
′𝐾
𝑖=1
√∑ 𝑤𝑖
2𝐾
𝑖=1
 , 
where 𝑤𝑖 = √𝑛𝑖, 𝑛𝑖 is a sample size for the 𝑖
𝑡ℎ study, and 𝑧𝑖
′ = sign(?̂?𝑖) Φ
−1 (
pi
2
), ?̂?𝑖 is 
an effect estimate for the 𝑖𝑡ℎ study. The test statistic follows a standard normal 
distribution under the null hypothesis of no effect.  
 
However, the major disadvantage of all of the p-value based approaches is that they do 
not provide a pooled effect size estimate. This disadvantage can be overcome by 
combining the effect sizes of the participating studies instead of the p-values. The 
inverse-variance-weighted fixed-effects (FE) model is commonly used to combine the 
effect size estimates of the studies assuming the effect size estimates are the same across 
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the individual studies estimating the same underlying effect (Fleiss 1993; Hedges and 
Olkin 1985). The inverse-variance-weighted pooled effect estimator is  
?̂?𝐹𝐸 =
∑ 𝑤𝑖?̂?𝑖
𝑁
𝑖=1
∑ 𝑤𝑖
𝑁
𝑖=1
 , 
where the weight 𝑤𝑖 =
1
𝑠𝑖
2, and ?̂?𝑖 and 𝑠𝑖 are the effect estimate and the standard error of 
the effect estimate for the 𝑖𝑡ℎ study. The standard error of ?̂?𝐹𝐸 is SE(?̂?𝐹𝐸  ) =  
1
√∑ 𝑤𝑖
𝑁
𝑖=1
. 
Hence the test statistic of FE model is  
𝑍𝐹𝐸 =
?̂?𝐹𝐸
SE(?̂?𝐹𝐸)
=
∑ 𝑤𝑖?̂?𝑖
𝑁
𝑖=1
√∑ 𝑤𝑖
𝑁
𝑖=1
 . 
Under the null hypothesis of no effect, the test statistic of the FE model, 𝑍𝐹𝐸 , follows a 
standard normal distribution. The FE model assumes a common true underlying effect 
parameter for all studies. 
 
1.3 Meta-Analysis of Potentially Heterogeneous Studies 
The FE meta-analysis model depends on the homogeneity assumption that the true effect 
for all studies is the same. Thus, when the true effects across studies differ, the FE model 
is not appropriate. It violates the assumption of homogeneity of effect size, ignores the 
between-study variance, and so is likely to lead to confidence intervals of the pooled 
effect size estimate with lower coverage probability than expected.  
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We can formally test for effect size homogeneity using Cochran’s Q statistic (Cochran 
1952). The Q statistic is calculated by summing the squared differences of each study’s 
estimated effect from the pooled effect size, weighted by its inverse variance, 
𝑄 = ∑
(?̂?𝑖 − ?̂?𝐹𝐸)
2
𝑉𝑎𝑟(?̂?𝑖)
𝐾
𝑖=1
 . 
Under the null hypothesis of homogeneity among the effect sizes, the Q statistic follows a 
Chi-square distribution with K-1 degrees of freedom where K indicates the number of 
participating studies in the meta-analysis. If the null hypothesis is not rejected, the FE 
model is adopted in the meta-analysis while rejecting the null hypothesis indicates that 
the FE model is inappropriate to use.  
 
The Q statistic has low power when the number of studies is small.  Further, it also has 
excessive power when the number of studies is large, meaning that clinically unimportant 
differences in effect across studies may produce a significant Q statistic. (Hardy and 
Thompson 1998).  Also, the Q statistic only detects the presence or absence of 
heterogeneity among the effects, but does not provide a measure of the amount of 
heterogeneity. Thus, we can use the I2 statistic, which can be computed from the Q 
statistic, 
𝐼2 =
𝑄 − (𝐾 − 1)
𝑄
∗ 100% , 
where K indicates the number of studies in the meta-analysis and the interpretation is the 
percentage of total variation that is due to heterogeneity rather than sampling error 
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(Higgins and Thompson 2002). The values of I2 range from 0% to 100% where 0% 
indicates all variability in the effect sizes is due to sampling error and none is due to 
heterogeneity. The I2 statistic is useful especially when the Q statistic does not reject the 
null hypothesis of homogeneity due to the small number of studies, the I2 statistic further 
quantifies the impact of the heterogeneity and provides more information on how much 
of the total variability is due to heterogeneity in the effect sizes. If the Q statistic reject 
the null hypothesis I2 still quantifies the impact of heterogeneity on the total variability. 
Higgins and Thompson (2002) suggest that a value of I2 greater than 50% might indicate 
substantial heterogeneity across the effect sizes. I2 is closely related to the between-study 
variance, 𝜏2, such that as 𝜏2 increases the value of I2 increases. But the advantage of I2 
over 𝜏2 is that I2 values can be directly compared between meta-analyses regardless of 
the number of studies and effect size metric.  
 
In the presence of heterogeneity, a random-effects (RE) model, instead of a FE model, 
can be used. The RE model accounts for heterogeneity in the effect sizes across the 
individual studies. The RE model correctly estimates the between-study variance and 
provides more appropriate confidence intervals for the pooled effect size estimate (Fleiss 
1993; Hedges and Olkin 1985). The inverse-variance-weighted pooled effect estimator is 
?̂?𝑅𝐸 =
∑ 𝑤𝑖
∗?̂?𝑖
𝑁
𝑖=1
∑ 𝑤𝑖
∗𝑁
𝑖=1
 , 
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where the weight 𝑤𝑖
∗ =
1
𝑠𝑖
2+?̂?2
 and the between-study variance, ?̂?2, can be estimated using 
DerSimonian and Laird’s method of moments (DerSimonian and Laird 1986). The 
standard error of ?̂?𝑅𝐸  is SE(?̂?𝑅𝐸  ) =  
1
√∑ 𝑤𝑖
∗𝑁
𝑖=1
. The test statistic of RE model is  
𝑍𝑅𝐸 =
?̂?𝑅𝐸
SE(?̂?𝑅𝐸)
=
∑ 𝑤𝑖
∗?̂?𝑖
𝑁
𝑖=1
√∑ 𝑤𝑖
∗𝑁
𝑖=1
 . 
 
1.3.1 Trans-ethnic Heterogeneity 
Until recently, most GWAS meta-analyses were conducted among studies with similar 
ancestry populations rather than incorporating studies from multiple ethnic populations. 
However, trans-ethnic meta-analysis or meta-analysis of GWAS from diverse ancestry 
populations is becoming increasingly popular. Although most GWAS originally focused 
on European-ancestry populations, the increased number of GWAS in other ethnic 
populations enables trans-ethnic meta-analysis. Combining GWAS from ethnically-
diverse populations through meta-analysis offers many advantages, such as increased 
statistical power through increased total sample size, prioritizes loci that are associated 
with multiple populations over loci that are population-specific for secondary replication, 
and fine-maps underlying functional variants (Y. Li and Keating 2014).  
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With these opportunities and advantages, the trans-ethnic meta-analysis also presents 
challenges. Because genetic architectures are not the same across diverse populations, it 
is not clearly understood how to leverage the ancestral genetic differences. Inconsistent 
LD patterns along with different allele frequency spectra can result in different sets of 
associated markers for complex traits and limit replicability across populations.  It is not 
clear how to optimize power for novel discovery versus fine-mapping when some loci are 
shared across populations and some are population-specific. Therefore, it is critical to 
properly incorporate heterogeneity that arises from the ancestral genetic differences in 
trans-ethnic studies.   
  
1.3.2 Covariate Heterogeneity 
In addition to the heterogeneity due to the genetic architecture differences in diverse 
populations, environmental exposures can further introduce variability in effect sizes 
across studies. Hence, it is important to investigate potential sources of heterogeneity 
when performing meta-analysis. Variability of environmental factors such as age, sex, 
body mass index (BMI), drug dosage, or duration of a certain exposure across studies can 
alter or confound treatment effects on outcomes. Hence, in clinical trials, meta-analysis 
can be used to examine the effect of those factors beyond the treatment effects and how 
those factors alter treatment effectiveness (Colditz et al. 1994). In statistical genetics, 
many efforts have been made to understand heterogeneity that arises from environmental 
factors other than genetic structure as well as the interplay of gene and environment 
10 
 
 
 
factors (Lebrec, Stijnen, and van Houwelingen 2010; Manning et al. 2011; X Wang et al. 
2009; Kraft et al. 2007; Herbert et al. 2006).  
 
When investigating the effects of environmental factors on the main effect of interest, the 
analysis approaches depend on the availability of data. Meta-regression is a useful tool 
when only study-level summary data are available.  This regression-based method uses 
the estimated effect sizes from each study as a dependent variable and one or more study-
level covariate measures as independent variables. Alternatively, meta-analysis of 
interaction-term estimates or a joint test of the main and interaction effects can be 
performed (Kraft et al. 2007; Manning et al. 2011). Finally, when full individual 
participant data is available we can model the pooled data including the interaction term 
using a mixed model. Although the individual participant data analysis allows an 
extended scope of analysis, if feasible, the collection of all data on all the participant 
individuals may take considerable time, resources and permissions to share such data. 
 
 
1.4 Dissertation Outline 
This dissertation includes three projects related to meta-analysis of potentially 
heterogeneous studies. Each project involves an evaluation of existing approaches and/or 
a novel approach, extensive simulation studies and comparisons to existing methods with 
a goal of properly dealing with heterogeneity that arises from genetic structure or other 
study characteristic differences across studies.  
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In chapter 2, we evaluate a two-stage approach for trans-ethnic meta-analysis in GWAS. 
We perform extensive simulation studies to compare five existing methods using one- 
and two-stage clustering approaches. We aim to show that the two-stage approach can be 
an effective and efficient approach using existing meta-analytic models when 
synthesizing GWAS from multiple populations with different ancestries. 
 
In chapter 3, we develop a novel methodology as an extension to Han and Eskin’s 
approach (B. Han and Eskin 2011) to accommodate multiple sources of heterogeneity in 
meta-analysis. We propose a new meta-analytic model that can be used in the context of 
meta-analysis of heterogeneous studies. We assume that there are multiple sources of 
heterogeneity directly related to study-level characteristics and therefore incorporate 
study-level covariates as random effects using a linear mixed effects model. A Log-
Likelihood Ratio Test (LRT) is compared to a corrected null distribution to evaluate p-
values.  
 
In chapter 4, we propose a Score Test as an alternative to the LRT proposed in chapter 3. 
We construct an empirical distribution to evaluate p-values. 
 
In chapter 5, we conclude our findings and discuss future research directions.  
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In summary, we explore and develop statistical approaches to accommodate potential 
heterogeneity across studies to improve power and computational efficiency in meta-
analysis of heterogeneous studies of GWAS. 
 
13 
 
 
 
Chapter 2 Evaluation of a Two-Stage Approach in Trans-ethnic Meta-Analysis 
in Genome-Wide Association Studies 
2.1 Introduction 
GWAS have identified many genetic loci contributing to the variation of complex human 
diseases (Welter et al. 2014; Mahajan et al. 2014; Morris et al. 2012; L. A. Hindorff et al. 
2009; L. Hindorff et al.).  Despite this success, the effect sizes of these loci are usually 
modest so that a large number of samples are needed and the analysis in any single study 
is likely under powered (McCarthy et al. 2008; Manolio et al. 2009). Moreover, the 
identified genetic variants from GWAS may not be the true causal variants but may only 
be in LD with nearby causal variants (Morris 2011). 
 
Meta-analysis is an effective approach to combine multiple GWAS and increase power 
by boosting sample sizes. Such meta-analysis has typically been conducted under a fixed-
effects model among studies with similar ancestry to avoid violation of the assumption of 
between-study effect homogeneity (Cantor, Lange, and Sinsheimer 2010; de Bakker et al. 
2008; Zeggini and Ioannidis 2009). Because meta-analysis has become more popular and 
feasible through the use of comprehensive reference panels such as the International 
HapMap Project (Altshuler et al. 2010) and the 1000 Genome Project (Abecasis et al. 
2010) permitting good quality genotype imputations, the number of GWAS meta-
analyses, restricted to a single ancestry group and across multiple different populations, 
has increased. However, it remains unclear how to better leverage the allelic 
heterogeneity and different LD structure across populations of different ancestries since 
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the differences in the LD structure can cause effect heterogeneity. Properly analyzing 
association results from different ancestry samples can increase the sample size and 
hence may lead to higher power to identify novel loci that are similar across populations 
(Y. Li and Keating 2014). In addition, meta-analyses including populations of different 
genetic backgrounds may enhance the ability to fine-map causal signals by leveraging the 
differences in LD across ancestral groups (Franceschini et al. 2012; Liu et al. 2012; 
Boerwinkle and Heckbert 2014; Y. Li and Keating 2014; Liu et al. 2014). Therefore, 
while challenging, it is worth exploring approaches for meta-analysis of multiple GWAS 
across different ethnic ancestral populations.  
 
Conventional meta-analysis methods such as FE and RE models have been used in 
GWAS. These methods were developed in the clinical trial setting (Fleiss 1993; Hedges 
and Olkin 1985). The FE model assumes that the effect sizes are consistent across 
individual studies. If the underlying effects are not equal, the FE model does not properly 
incorporate heterogeneity among studies and underestimates the standard error of the 
combined effect estimates. RE models account for heterogeneity, correctly estimate the 
standard errors, and provide more appropriate confidence intervals for the effect 
estimates when effect size heterogeneity exists. Although these two conventional 
methods are useful, they may not always be suitable for GWAS. The FE model depends 
on a rather strong assumption of equal effect sizes across contributing studies and hence 
it is not appropriate when meta-analyzing GWAS over populations of different ancestry. 
The RE model is designed to handle heterogeneity; however, it relies on a conservative 
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assumption that effect sizes are different even under the null hypothesis of no association, 
thereby making the procedure more conservative in detecting genetic association. 
 
In addition to the two conventional methods, three methods were recently proposed 
specifically for meta-analysis of GWAS in the presence of heterogeneity of effect sizes 
across independent studies. To cope with low power and the conservativeness of the 
conventional RE model, Han and Eskin developed an alternative random-effects (RE-
HE) model that assumes no heterogeneity under the null hypothesis of no association(B. 
Han and Eskin 2011). Han and Eskin proposed a second method called binary-effects 
(BE) model (B. Han and Eskin 2012). It is called binary-effects model not because it 
takes a binary outcome but because we assume that the true effect is either present or 
absent in a study using the BE model. This method is based on a new statistic called the 
m-value, which is the posterior probability of the non-zero effect size of a study. The m-
values are calculated using all studies assuming the effect sizes are similar across studies 
if their effects are non-zero. The third method, Meta-analysis of Transethnic Association 
studies (MANTRA), uses a Bayesian framework to account for heterogeneity (Morris 
2011).  
 
In this chapter, we propose a two-stage clustering strategy in the context of trans-ethnic 
meta-analysis of GWAS. This approach utilizes prior knowledge of genetic dissimilarity 
across studies in terms of their mean allele frequency. Our goal is to explore the 
performance of the two-stage clustering approach in various simulation scenarios using 
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the five methods (RE, FE, RE-HE, BE and MANTRA), to suggest the best strategy in the 
meta-analysis of potentially heterogeneous studies, and to examine whether the two-stage 
approach offers any advantages over a one-stage approach.  
 
2.2 Methods 
2.2.1 Two-Stage Clustering Approach 
We apply five existing meta-analytic methods to trans-ethnic meta-analysis in a two-
stage clustering approach and compare to a one-stage (i.e., no clustering) approach. We 
assume that there are N independent studies. In the one-stage approach, we simply use the 
existing methods to meta-analyze over the N independent GWAS. In the two-stage 
approach, we utilize known study-specific information and group them into N* subgroups 
(N* ≤ N) according to the (dis)similarity of genetic characteristics; for example, 
ethnically closely-related studies are grouped into the same cluster and distantly-related 
studies are separated into different clusters.  
 
Any measure can be applied to evaluate the dissimilarity of the participating cohorts. We 
specifically evaluate the dissimilarity across the participating cohorts by calculating 
pairwise Euclidean distances of their average allele frequencies. The dissimilarity 
between samples from two cohorts is evaluated by the square root of the sum of squares 
of the average allele frequency differences of variants available in both cohorts. Initially, 
each cohort is assigned to its own and proceeds iteratively through a hierarchical 
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clustering algorithm. At each stage, it joins two closest clusters and continues until there 
is just a single cluster. We assume that the studies within each cluster have homogeneous 
effect sizes and we use an FE model among studies within each cluster. We implement 
the methods discussed below to combine FE-derived meta-analysis results across the 
different clusters in a two-stage approach. In practice, it is reasonable to use ethnic 
clustering such that studies from the same ethnic ancestry are allocated to the same 
cluster. We use clustering methods to identify those samples from similar genetic 
backgrounds. 
 
2.2.2 Fixed-effects model 
The FE model assumes a common true association effect parameter 𝛽 across N 
independent studies and provides a test statistic, testing H0: 𝛽 = 0 𝑣𝑠. H1: 𝛽 ≠ 0, using 
an inverse-variance-weighted pooled effect estimator and its standard error. Let 𝑏𝑖 be the 
effect estimate for the 𝑖𝑡ℎ study assumed to follow a normal distribution with the true 
effect size 𝛽 and variance 𝑠𝑖
2. Suppose the variance 𝑠𝑖
2 of each study is estimated and 
treated as the true variance for study 𝑖. The inverse-variance-weighted pooled effect 
estimator is  
 
?̂? =
∑ 𝑤𝑖𝑏𝑖
𝑁
𝑖=1
∑ 𝑤𝑖
𝑁
𝑖=1
 , 
 
18 
 
 
 
where the weight 𝑤𝑖 =
1
𝑠𝑖
2. The standard error of ?̂? is SE(?̂? ) =  
1
√∑ 𝑤𝑖
𝑁
𝑖=1
. Hence the test 
statistic of FE model is  
𝑍𝐹𝐸 =
?̂?
SE(?̂? )
=
∑ 𝑤𝑖𝑏𝑖
𝑁
𝑖=1
√∑ 𝑤𝑖
𝑁
𝑖=1
 . 
 
Under the null hypothesis of no association, the test statistic follows a standard normal 
distribution (Fleiss 1993; Hedges and Olkin 1985).  
 
2.2.3 Random-effects model 
The RE model assumes the true effect parameter 𝛽𝑖 for each study follows a normal 
distribution with mean population effect parameter β and between-study variance 𝜏2. The 
null and alternative hypotheses are H0: 𝛽 = 0, 𝜏
2 > 0 𝑣𝑠. H1: 𝛽 ≠ 0, 𝜏
2 > 0. The 
between-study variance 𝜏2 can be estimated by the method of moments using the 
DerSimonian and Laird approach (DerSimonian and Laird 1986). Given the estimated 
between-study variance ?̂?2, the inverse-variance-weighted pooled effect estimator ?̂?∗ and 
its standard error can be estimated in a similar way to that of the FE model except that the 
weight includes the between-study variance. The inverse-variance-weighted pooled effect 
estimator is 
 
?̂?∗ =
∑ 𝑤𝑖
∗𝑏𝑖
𝑁
𝑖=1
∑ 𝑤𝑖
∗𝑁
𝑖=1
 , 
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where the weight 𝑤𝑖
∗ =
1
𝑠𝑖
2+?̂?2
. The standard error of ?̂?∗ is SE(?̂?∗ ) =  
1
√∑ 𝑤𝑖
∗𝑁
𝑖=1
. Hence the 
test statistic of RE model is  
𝑍𝑅𝐸 =
?̂?∗
SE(?̂?∗)
=
∑ 𝑤𝑖
∗𝑏𝑖
𝑁
𝑖=1
√∑ 𝑤𝑖
∗𝑁
𝑖=1
 . 
 
Under the null hypothesis of no association (H0: 𝛽 = 0, 𝜏
2 > 0), the test statistic follows 
a standard normal distribution (Fleiss 1993; Hedges and Olkin 1985).  
 
2.2.4 Likelihood approach to RE model by Han and Eskin  
Han and Eskin propose a likelihood based method that assumes no heterogeneity under 
the null hypothesis of no association; hence the mean and between-study variance are 
equal to zero, while allowing for heterogeneity under the alternative. By relaxing the 
conservative assumption of heterogeneity under the null hypothesis of RE, the power of 
the RE-HE model is increased substantially compared to the conventional RE model. The 
likelihoods under the null (H0: 𝛽 = 0 and 𝜏
2 = 0) and the alternative (H1: 𝛽 ≠ 0 and 
𝜏2 ≠ 0) are 
 
𝐿0 = ∏
1
√2𝜋𝑠𝑖
2
𝑒𝑥 𝑝 (−
𝑏𝑖
2
2𝑠𝑖
2), 
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𝐿1 = ∏
1
√2𝜋(𝑠𝑖
2 + 𝜏2)
𝑒𝑥 𝑝 (−
(𝑏𝑖 − 𝛽)
2
2(𝑠𝑖
2 + 𝜏2)
), 
 
The notation is the same as the notation used in the description of the FE and RE models. 
The maximum likelihood estimates (MLE) for 𝛽 and 𝜏2 can be obtained by an iterative 
procedure suggested by Hardy and Thompson (Hardy and Thompson 1996). Given the 
estimated ?̂? and ?̂?2, the likelihood ratio test (LRT) statistic is constructed as follows 
 
𝑇𝑅𝐸𝐻𝐸 = −2 log (
sup𝐿0
sup𝐿1
) = ∑𝑙𝑜𝑔 (
𝑠𝑖
2
𝑠𝑖
2 + ?̂?2
) + ∑
𝑏𝑖
2
𝑠𝑖
2 − ∑
(𝑏𝑖 − ?̂?)
2
𝑠𝑖
2 + ?̂?2
 . 
 
The test statistic 𝑇𝑅𝐸𝐻𝐸 asymptotically follows an equal mixture of 𝜒1
2 and 𝜒2
2 
distributions when the number of studies is large. The asymptotic p-value is overly 
conservative when the number of studies is small due to the heavier tail of the asymptotic 
distribution compared to the true distribution at genome-wide significance level. Hence 
tabulated values provided by Han and Eskin are used for determining the statistical 
significance (B. Han and Eskin 2011).  
 
2.2.5 Binary Effects model  
The binary effects model is a new type of RE model, with newly proposed statistic called 
m-value and weighted z-score. The z-score (𝑍𝑖) is defined by the observed effect size (𝑏𝑖) 
21 
 
 
 
divided by its standard error (𝑠𝑖) for the 𝑖
𝑡ℎ study. The m-value, ranging from 0 to 1, can 
be interpreted as the posterior probability that the effect is non-zero in each study in a 
meta-analysis. The test statistic of the BE model (𝑇𝐵𝐸) is a weighted sum of z-scores, 
where greater weight is assigned to studies that are expected to have a non-zero effect (by 
incorporating the m-values). The test statistic is  
 
𝑇𝐵𝐸 =
∑𝑚𝑖√𝑤𝑖𝑍𝑖
√∑𝑚𝑖
2𝑤𝑖
 , 
 
where the m-value is computed by 𝑚𝑖 = 𝑃(𝑇𝑖 = 1|𝑏) =
𝑃(𝑏|𝑇𝑖 = 1)𝑃(𝑇𝑖=1)
𝑃(𝑏|𝑇𝑖 = 0)𝑃(𝑇𝑖=0)+𝑃(𝑏|𝑇𝑖 = 1)𝑃(𝑇𝑖=1)
, 𝑏 is a vector of the observed effect sizes, 𝑇𝑖 is a 
random variable that has a value 1 if the 𝑖𝑡ℎ study has an effect and 0 otherwise. The prior 
probability of each study having an effect, 𝑃(𝑇𝑖 = 1), assumes a beta prior and the 
observed effect size, 𝑏𝑖 assumes a 𝑁(𝛽, 𝑠𝑖
2). A Markov Chain Monte Carlo (MCMC) 
method is proposed to estimate the m-value (B. Han and Eskin 2012). In their proposed 
MCMC method, they start from a random 𝑇 = 𝑡 and choose a next 𝑡′. 𝑔(𝑡) is 
proportional to a posterior probability of 𝑇 given the observed effect sizes such that 
𝑔(𝑡) = 𝑃(𝑏|𝑇 = 𝑡)𝑃(𝑇 = 𝑡) ∝ 𝑃(𝑇 = 𝑡|𝑏). If 𝑔(𝑡) < 𝑔(𝑡′) then move to 𝑡′. Otherwise, 
move to 𝑡′ with probability 𝑔(𝑡′)/𝑔(𝑡). They repeat this MCMC method for the 
approximations of the m-values. 𝑧𝑖 = 𝑏𝑖/𝑠𝑖 is the z-score and the weight can be 
approximated by √𝑤𝑖 ≈ √𝑛𝑖  𝑚𝑎𝑓𝑖(1 − 𝑚𝑎𝑓𝑖) where 𝑛𝑖 is the sample size and 𝑚𝑎𝑓𝑖 is 
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the minor allele frequency (MAF) for the ith study (Zaitlen and Eskin 2010). If the MAFs 
are similar among studies the weight √𝑤𝑖 approximates √𝑛𝑖 (de Bakker et al. 2008).   
 
2.2.6 Meta-analysis of Transethnic Association studies  
Morris developed this method in a Bayesian framework and implemented it in the 
MANTRA software (Morris 2011). It takes into account the estimated similarity among 
studies with respect to genetic relatedness using a Bayesian partition model (Denison and 
Holmes 2001; Knorr-Held and Rasser 2000) and takes genetic distance between studies 
into account. This approach exploits the notion that similar studies are more likely to 
have similar effect sizes, while dissimilar studies should, in principle, have more variable 
effect estimates. The statistical evidence of association is evaluated by the Bayes’ factor 
(BF) (Kass and Raftery 1995); that is, 
 
𝛬 =
𝑓(𝒃, 𝒔|𝑀1)
𝑓(𝒃, 𝒔|𝑀0)
 , 
 
where 𝒃 and 𝒔 are vectors of the observed allelic effects 𝑏𝑖 and respective standard errors 
𝑠𝑖 from all studies and assume to be known values. We assume 𝑏𝑖~N(𝛽𝑖, 𝑠𝑖) where 𝛽𝑖 
denotes the true allelic effect. Under the null model (𝑀0), there is no association of a 
variant with a trait in any population, 𝛽𝑖 = 0 for all 𝑖, while the alternative model (𝑀1) 
corresponds to not all 𝛽𝑖 = 0. The marginal likelihood of the observed allelic effects 
under model 𝑀  
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𝑓(𝒃, 𝒔|𝑀) ∝ ∫ 𝑓(𝒃, 𝒔|𝜽)𝑓(𝜽|𝑀
𝜃
)𝜕𝜽 
 
is given by the integration over the unknown parameters, θ, including study-specific true 
allelic effect 𝛽𝑖 and additional hyper-parameters relating to their prior distribution, where 
the likelihood  
 
𝑓(𝒃, 𝒔|𝜽) = 𝑓(𝒃, 𝒔|𝜷) = ∑𝑓(𝑏𝑖, 𝑠𝑖|𝛽𝑖)
𝑁
𝑖=1
 
and  
𝑓(𝑏𝑖, 𝑠𝑖|𝛽𝑖) ∝
1
𝑠𝑖
exp [−
(𝑏𝑖 − 𝛽𝑖)
2
2𝑠𝑖
2 ] 
 
The marginal likelihood 𝑓(𝒃, 𝒔|𝑀) cannot be directly evaluated; however, the joint 
posterior density can be approximated by a Metropolis-Hastings MCMC algorithm. The 
hyper-parameters of θ include the number of clusters and cluster centers, and th number 
of clusters are addressed by a birth-death process through a reversible-jump step in the 
MCMC algorithm. The number of clusters determine the dimensionality of θ. The 
MCMC algorithm is run for initial burn-in period to allow convergence from randomly 
assigned starting values for θ (Morris 2011). After convergence, the marginal likelihood  
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𝑓(𝒃, 𝒔|𝑀) is approximated by the harmonic mean of sampled likelihood values (Newton 
and Raftery 1994). 
 
 
2.3 Simulation Study Design 
We performed a simulation study to compare the type I error and power of the one- and 
two-stage clustering approaches using the five methods, with the goal of identifying more 
efficient meta-analysis strategies for trans-ethnic studies.   
 
We used haplotype data from the International HapMap Project Phase 3 (HapMap3) 
(Altshuler et al. 2010) haplotype data to simulate genotypes for 10 populations. In the 
HapMap3 data, there were four African-ancestry (AfA) cohorts (African ancestry in 
Southwest USA (ASW), Luhya in Webuye, Kenya (LWK), Maasai in Kinyawa, Kenya 
(MKK), Yoruba in Ibadan, Nigeria (YRI)) and two Asian-ancestry (AsA) cohorts 
(Chinese in Metropolitan Denver (CHD), Japanese in Tokyo and Han Chinese in Beijing 
(JPT+ CHB)), two European-ancestry (EuA) cohorts (Utah residents with North and 
Western European ancestry (CEU), Toscani in Italy (TSI)), one Mexican (Mexican 
ancestry in Los Angeles (MEX)) and one Gujarati Indian (Gujarati Indians in Houston 
(GIH)). The pairwise dissimilarity metric among all ten populations is presented in the 
Table 2.1. A smaller distance between two studies indicates closer genetic relatedness. 
We graphically show the two-stage clustering approach using a dendrogram (Figure 2.1). 
In Figure 2.1, a threshold at 0.25 of the dissimilarity metric would leave three clusters, 
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and studies within a cluster are relatively close to each other as measured by genetic 
distance, while studies in different clusters are further apart. Based on this, we grouped 
the two EuA cohorts with the MEX and GIH cohorts together as GEM (GIH + EuA + 
MEX) studies because these four cohorts cluster together as shown below. And we also 
grouped the African populations (AfA) and the Asian populations (AsA). 
 
We simulated genotypes of variants on chromosome 21 using HAPGEN2 software (Su, 
Marchini, and Donnelly 2011) which simulated genotypes based on a reference set of 
haplotypes and an estimate of the recombination rate across a region. Here, we used the 
HapMap3 data as a reference set for each of the 10 populations. Thus, the simulated data 
shared LD patterns similar to the HapMap3 reference data. For each simulation replicate, 
we generated a continuous trait Y for a study-specific association analysis from a normal 
distribution with mean β and standard deviation 1, 𝛽~𝑁(𝛽, 1), where the value of β 
depends on each scenario.  
 
Under the null hypothesis of no association, we simulated 1,000 replicates (11,575,000 
null single nucleotide polymorphisms (SNPs)) to evaluate Type I error for the one- and 
two-stage approaches for the FE, RE, RE-HE, BE and MANTRA methods at varying 
asymptotic thresholds (for α = 0.05 through 0.0001). A continuous trait Y was generated 
from a normal distribution with mean 0 and standard deviation 1. We pooled all the 
variants from the 1,000 replicates and assess type I error by calculating the proportion of 
SNPs whose meta-analytic p-value was less than pre-specified asymptotic thresholds. For 
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the Bayesian method MANTRA, we only presented the proportion of SNPs with BF 
greater than preselected thresholds because there was no metric to convert BFs to p-
values (Xu Wang et al. 2013). 
 
For power analyses, we considered four heterogeneity scenarios: (1) Effect-size 
homogeneity, (2) Ancestry-specific effects, (3) Effect-size heterogeneity, and (4) Western 
exposure effects. In the Effect-size homogeneity scenario (scenario 1), all 10 studies have 
the same effects and therefore there is no heterogeneity across the studies. In the 
Ancestry-specific scenario (scenario 2), we considered only studies in one ancestry 
cluster to have non-zero effects. Specifically, we assumed that the four AfA studies have 
non-zero allelic effects while all others have effect size 0 and we named it as the African-
specific effects scenario. In the Effect-size heterogeneity scenario (scenario 3), a SNP has 
an effect in multiple studies, assuming the same effect size among studies in the same 
ethnic group but allowing the effect size to vary across different ethnic groups (effect 
sizes: 0.05 for four AfA studies, 0.025 for two AsA studies and 0.0125 for four GEM 
studies). In the Western exposure effects scenario (scenario 4), we assumed that shared 
environments such as life style would result in similar genetic effects and hence we 
assigned equal, non-zero effect size to the causal variants only in the samples living in 
Europe or North America (ASW, CHD, CEU and TSI) regardless of their ethnicity. For 
scenarios 1, 2 and 4, we assessed power varying effect sizes from 0.05 to 0.2, which is 
roughly equivalent to 0.045% to 0.72% of the trait variation explained by a SNP with 
MAF 0.1.  
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We picked six causal SNPs based on their allele frequency as follows. Four SNPs had 
comparable effect allele frequency (EAF) (0.05, 0.1, 0.2, and 0.4, respectively) across the 
10 studies. The remaining two causal SNPs had varying allele frequencies for a selected 
allele across studies: one SNP with EAF in a range of 0.2 to 0.5 and the other with 
frequency between 0.2 and 0.8. Because there was no unified threshold to compare 
Frequentist and Bayesian methods, we assessed empirical thresholds for all five methods 
for the two clustering approaches under the null hypothesis of no association by pooling 
the p-values or BFs of the null variants and determining the desired quantile as the 
empirical thresholds (Table 2.2). We calculated the power for a single variant analysis by 
the proportion of the simulation replicates with a causal SNP association p-value less 
than or BF greater than the empirical thresholds for each meta-analysis method and 
clustering approach.  
 
We also calculated region-wise power using single variant analyses adjusting for multiple 
testing. In most genetic studies, the causal variants are often not available for analysis. In 
many cases, identified associated genetic variants are not the causal variants but in LD 
with those variants. Therefore, it is worthwhile to explore the surrounding region of a 
causal variant, including or excluding the causal variant, and to evaluate the performance 
of the two-stage clustering approach. We defined the regions of the six causal SNPs by 
start and end positions including all SNPs with 𝑟2>0.2 with the causal SNPs on Chr21, 
totaling to 652 SNPs for the six causal SNPs, and assessed power in those regions with 
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and without the causal SNPs. We defined the regions by 𝑟2 because we knew the causal 
SNPs and were interested in examining how LD with the causal variants would influence 
power. However, in practice, we may not know the causal variants and selecting a region 
based on location (e.g., a gene location) would be more practical. We defined statistical 
significance in the region-wise analysis by comparing the p-values or BFs of all SNPs in 
a region to an empirical threshold after adjusting for multiple testing. As above, we used 
empirical thresholds to evaluate power. To correct for multiple comparisons, we used a 
minimum p-value or a maximum BF of a region from each replicate to construct the 
empirical distribution. We then select the empirical threshold at the multiple testing 
adjusted threshold 𝛼 = 0.1 based on this empirical distribution. The multiple testing 
adjusted threshold 𝛼 = 0.1 may be interpreted as 𝛼 level divided by the number of SNPs 
to test in each region. The empirical thresholds are presented in the Tables 2.3 and 2.4. 
 
Once the genotypes and the phenotype were simulated, we performed association 
analysis using SNPTEST v2 (Marchini and Howie 2010) on common variants 
(MAF>3%, 11,575 SNPs) for the ten studies and then ran the trans-ethnic meta-analysis 
using METASOFT and MANTRA software. For the one-stage (no clustering) approach, 
we ran FE, RE, RE-HE, BE and MANTRA over the ten studies. For the two-stage 
approach, we first applied FE model within each of three clusters, AfA, AsA and GEM, 
to get cluster-specific summary results and then ran FE, RE, RE-HE, BE and MANTRA 
across the three clusters. For the equal sample size scenario, each study contained a 
sample size of 3,000 and hence 30,000 subjects in total were available for meta-analysis. 
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For the unequal sample size scenario, we increased sample size in the AfA studies by 1.5 
times (4,500) and decreased the sample size in the other ancestry studies by 2/3 (2,000) 
so that the total sample size (30,000) was the same as the equal sample size situation.
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Table 2.1 Pairwise dissimilarity metric in ten populations using Euclidean distance of average allele frequencies on 
Chromosome 21 
 ASW CEU CHD GIH JPT+CHB LWK MEX MKK TSI YRI 
ASW 0 0.408 0.461 0.379 0.459 0.162 0.389 0.122 0.397 0.174 
CEU 0.408 0 0.358 0.172 0.351 0.491 0.189 0.425 0.080 0.502 
CHD 0.461 0.358 0 0.305 0.074 0.516 0.287 0.470 0.356 0.523 
GIH 0.379 0.172 0.305 0 0.297 0.463 0.179 0.397 0.167 0.475 
JPT+CHB 0.459 0.351 0.074 0.297 0 0.517 0.278 0.470 0.349 0.525 
LWK 0.162 0.491 0.516 0.463 0.517 0 0.471 0.139 0.482 0.095 
MEX 0.389 0.189 0.287 0.179 0.278 0.471 0 0.408 0.189 0.482 
MKK 0.122 0.425 0.470 0.397 0.470 0.139 0.408 0 0.414 0.166 
TSI 0.397 0.080 0.356 0.167 0.349 0.482 0.189 0.414 0 0.493 
YRI 0.174 0.502 0.523 0.475 0.525 0.095 0.482 0.166 0.493 0 
The dissimilarity between samples from two cohorts is evaluated by the square root of the sum of squares of the average allele 
frequency differences of variants available in both cohorts. A smaller distance between two studies indicates closer genetic 
relatedness in terms of their allele frequencies. Higher values mean greater dis-similarity. 
Population samples from: African ancestry in Southwest USA (ASW); Utah residents with North and Western European 
ancestry (CEU); Chinese in Metropolitan Denver (CHD); Gujarati Indians in Houston (GIH); Japanese in Tokyo and Han 
Chinese in Beijing (JPT+ CHB); Luhya in Webuye, Kenya (LWK); Mexican ancestry in Los Angeles (MEX); Maasai in 
Kinyawa, Kenya (MKK); Toscani in Italy (TSI); and Yoruba in Ibadan, Nigeria (YRI).  
We used all the common variants on Chromosome 21 (11,575 variants) to calculate the dissimilarity matrix for ten studies. The 
computation was fast and took less than a second even using a PC (Intel® Core™ i7-2600 Processor, 8M Cache, 3.4 GHz). 
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Table 2.2 Empirical thresholds for one- and two-stage clustering approaches for FE, RE, RE-HE, BE and MANTRA methods 
when sample sizes are equal 
 One-stage clustering approach Two-stage clustering approach 
Threshold FE RE RE-HE BE MANTRA 
FE 
2-stage 
RE 
2-stage 
RE-HE 
2-stage 
BE 
2-stage 
MANTRA 
2-stage 
5e-2 5.0E-02 6.4E-02 5.0E-02 5.0E-02 0.35 5.0E-02 6.7E-02 5.1E-02 5.0E-02 0.35 
1e-2 1.0E-03 1.4E-02 1.0E-02 9.9E-03 0.97 1.0E-03 1.4E-02 1.0E-02 9.9E-03 0.96 
1e-3 9.9E-04 1.5E-03 1.0E-03 9.7E-04 1.9 9.9E-04 1.5E-03 1.0E-03 9.8E-04 1.9 
1e-4 1.0E-04 1.6E-04 1.0E-04 1.0E-04 2.8 1.0E-04 1.6E-04 1.0E-04 1.0E-04 2.8 
The left most column is the asymptotic threshold for the one-stage and the two-stage clustering approaches. Other columns 
provide empirical thresholds for Fixed-Effects (FE), Random-Effects (RE), Random-Effects model of Han and Eskin (RE-
HE), Binary Effects (BE) model and Meta-analysis of Transethnic Association studies (MANTRA) models. 
 
Table 2.3 Empirical thresholds adjusting for the multiple testing for both one-stage and two-stage clustering approaches for 
FE, RE, RE-HE, BE and MANTRA methods for region-wise analyses including causal variants 
 One-stage clustering approach Two-stage clustering approach 
Causal SNP FE RE RE-HE BE MANTRA 
FE 
2-stage 
RE 
2-stage 
RE-HE 
2-stage 
BE 
2-stage 
MANTRA 
2-stage 
EAF=0.05 1.30E-03 1.80E-03 1.30E-03 1.30E-03 1.8 1.30E-03 1.70E-03 1.30E-03 1.40E-03 1.8 
EAF=0.1 2.20E-03 3.10E-03 2.20E-03 1.90E-03 1.6 2.20E-03 3.10E-03 2.30E-03 2.10E-03 1.6 
EAF=0.2 1.30E-03 1.80E-03 1.20E-03 1.20E-03 1.8 1.30E-03 1.90E-03 1.20E-03 1.00E-03 1.8 
EAF=0.4 1.80E-03 2.50E-03 1.60E-03 1.50E-03 1.7 1.80E-03 2.20E-03 1.80E-03 1.70E-03 1.7 
EAF=0.2~0.5 2.80E-03 3.80E-03 2.20E-03 2.30E-03 1.5 2.80E-03 3.60E-03 2.70E-03 2.70E-03 1.5 
EAF=0.2~0.8 5.20E-03 7.40E-03 5.20E-03 5.00E-03 1.2 5.20E-03 7.00E-03 5.80E-03 6.60E-03 1.2 
The left most column is the effect allele frequency (EAF) or the range of the EAF of the causal SNPs across the ten 
populations. 
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Table 2.4 Empirical thresholds adjusting for the multiple testing for both one- and two-stage clustering approaches for FE, RE, 
RE-HE, BE and MANTRA methods for region-based analyses excluding causal variants 
 One-stage clustering approach Two-stage clustering approach 
Causal SNP FE RE RE-HE BE MANTRA 
FE 
2-stage 
RE 
2-stage 
RE-HE 
2-stage 
BE 
2-stage 
MANTRA 
2-stage 
EAF=0.05 1.3E-03 1.8E-03 1.3E-03 1.3E-03 1.8 1.3E-03 1.7E-03 1.3E-03 1.4E-03 1.8 
EAF=0.1 2.2E-03 3.1E-03 2.2E-03 1.9E-03 1.6 2.2E-03 3.1E-03 2.3E-03 2.1E-03 1.6 
EAF=0.2 1.3E-03 1.8E-03 1.2E-03 1.2E-03 1.8 1.3E-03 1.9E-03 1.2E-03 1.0E-03 1.8 
EAF=0.4 1.8E-03 2.5E-03 1.6E-03 1.5E-03 1.7 1.8E-03 2.2E-03 1.8E-03 1.7E-03 1.7 
EAF=0.2~0.5 2.8E-03 3.8E-03 2.2E-03 2.3E-03 1.5 2.8E-03 3.6E-03 2.7E-03 2.7E-03 1.5 
EAF=0.2~0.8 5.2E-03 7.4E-03 5.2E-03 5.0E-03 1.2 5.2E-03 7.0E-03 5.8E-03 6.6E-03 1.2 
The left most column is the effect allele frequency (EAF) or the range of the EAF of the causal SNPs across the ten 
populations. 
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Figure 2.1 Dendrogram showing the dissimilarity among ten populations from the 
International HapMap Project Phase 3 data 
 
The distance between populations represents a Euclidean distance calculated using allele 
frequencies. A smaller distance between populations indicates closer genetic relatedness. 
The red dotted line indicates an arbitrary but clear fixed threshold at 0.25 in distance that 
leaves three clusters where studies within a cluster are relatively close to each other in 
their genetic relatedness.  
Population samples are from: African ancestry in Southwest USA (ASW); Utah residents 
with North and Western European ancestry (CEU); Chinese in Metropolitan Denver 
(CHD); Gujarati Indians in Houston (GIH); Japanese in Tokyo and Han Chinese in 
Beijing (JPT+ CHB); Luhya in Webuye, Kenya (LWK); Mexican ancestry in Los 
Angeles (MEX); Maasai in Kinyawa, Kenya (MKK); Toscani in Italy (TSI); and Yoruba 
in Ibadan, Nigeria (YRI).  
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2.4 Simulation Results 
2.4.1 Type I error 
Table 2.5 shows that the four Frequentist methods (FE, RE, RE-HE, BE) of one- and 
two-stage approaches had type I error that were less than or equal to the pre-selected 
𝛼 levels. The RE model was consistently conservative. We could not evaluate type I error 
of MANTRA against the asymptotic thresholds because it uses BFs. Instead, we present 
the proportion of SNPs whose BF was greater than a few, preselected thresholds for 
MANTRA. In the unequal sample size scenario, the type I error rates (Table 2.6) and the 
empirical thresholds (Table 2.7) were similar to the equal sample size situation. 
 
2.4.2 Power 
2.4.2.1 Equal Sample Size Scenario 
To evaluate power, we considered four scenarios as described above. In all power 
scenarios, we compared 1) the two-stage approach to the one-stage approach for the five 
aforementioned methods, 2) the recent methods (RE-HE, BE and MANTRA) to the 
conventional FE and RE methods in both one- and two-stage approaches, and 3) all of the 
ten combinations (five methods by the one- and two-clustering approaches) to see which 
one is the most powerful in each scenario. We used empirical thresholds for power 
analysis because there was no unified threshold to compare Frequentist and Bayesian 
methods. The statistical significance for comparison among the approaches and methods 
was assessed by comparing 95% confidence intervals. 
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For scenario 1, where there was no heterogeneity in effect sizes across the studies, all 
meta-analysis methods in both clustering approaches showed similar power. The 
differences between the corresponding two- and one-stage methods were trivial except in 
the two-stage conventional RE model (Figure 2.2A). The RE model showed slightly 
higher power in the one-stage analysis than in the two-stage approach. 
 
In the Ancestry-specific effect size (scenario 2) and the Effect-size heterogeneity 
(scenario 3) scenarios, we introduced heterogeneity in the effect sizes according to the 
population ancestry. In the Ancestry-specific effect size scenario (Figure 2.2B), we set 
the African-ancestry studies to have equal, non-zero effect sizes. We observed a 
significant power increase in the 2-stage BE model when 𝛽=0.15 compared to its one-
stage counterpart as their 95% confidence intervals overlapped. In general, the 2-stage 
approach of all the other models had either higher or similar power numerically 
compared to their one-stage counterparts but their 95% confidence intervals did not 
overlap. In both clustering approaches, the recent meta-analytic methods (RE-HE, BE 
and MANTRA) performed significantly better than the conventional methods (FE and 
RE) as their confidence intervals did not overlap. Among the recent methods, the two-
stage BE model was significantly more powerful than the one-stage RE-HE and one-
stage BE models as their confidence intervals did not overlap and marginally better than 
the two-stage RE-HE and MANTRA in the one- and two-stage approaches.  
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In the Effects-size heterogeneity scenario (scenario 3), we varied the size of the effect for 
the populations in the different ethnic clusters while the effect sizes were equal across 
studies within a cluster. Therefore, the heterogeneity arose from different magnitude of 
positive effect sizes across the clusters. In Figure 2.2C, we show power over six allele 
frequency scenarios. The two-stage approaches showed slightly higher or similar power 
compared to the same methods in the one-stage approach except for the RE model 
(Figure 2.2C). The two-stage BE model consistently appeared numerically more 
powerful than the other models but it was only significantly different from both one- and 
two-stage RE models. Interestingly, a variant with EAF of 0.4 (observed average EAF 
over 10 studies was 0.394, observed EAF=0.358~0.427) was more powerful than a 
variant with EAF=0.2~0.5 (observed average EAF was 0.366, observed 
EAF=0.206~0.494) in both two-stage and one-stage approaches. Although the variant 
with EAF=0.4 had slightly higher observed average EAF, a variant that was consistently 
present across different ethnicities in terms of allele frequency seemed to be better 
aggregated in a meta-analysis stage compared to a variant with somewhat diverse EAFs 
across different populations. 
 
In the Western exposure effects scenario (scenario 4), among the recent methods (RE-
HE, BE and MANTRA), the two-stage approach was significantly (RE-HE and BE) or 
nominally (MANTRA) less powerful compared to the one-stage approach (Figure 2.2D). 
This finding was expected, because we clustered the studies according to the dissimilarity 
of mean allele frequency and therefore the true source of heterogeneity in the effect size 
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was not correctly taken into consideration. As a result, studies in each cluster remained 
heterogeneous and therefore using the FE model over the heterogeneous studies (the two-
stage approach) reduced power. In this situation, the one-stage approach was more 
powerful. Interestingly, we observed the opposite phenomenon in the RE model. The 
two-stage RE model was more powerful than the one-stage RE model. This contrast 
suggests that, despite its power loss over heterogeneous studies, the prior use of the FE in 
the 2-stage RE model was more beneficial than the one-stage RE model.  
 
2.4.2.2 Unequal Sample Size Scenario 
We also considered unequal sample size scenarios since that is typical of real genetic 
study meta-analyses. In the unequal sample size situation, we increased the sample size 
(as described in the simulation study) in the AfA studies while decreased in the other 
studies to keep the total sample size the same. We observed improved power as expected 
due to the increased sample size in the AfA studies because the simulation model 
included a true effect in the AfA samples only, while there were no simulated effects in 
samples from other ancestries. We show the unequal size simulation results in the 
scenarios 2 and 3 in comparison to the equal sample size results (Figure 2.3A and 2.3C).  
 
2.4.2.3 Sensitivity Analysis of The Two-Stage Clustering Approach 
We also examined the sensitivity of our two-stage clustering approach in additional 
simulations by varying the threshold to a different value of the dissimilarity metric in 
Figure 2.1, resulting in a different number of clusters. Moving the threshold up from 0.25 
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to 0.4 results in two clusters: four AfA studies in one cluster and the rest of the studies 
belonging to the other cluster (2 Clusters). We can also move the threshold down such 
that we may have five clusters from Figure 2.1 where each cluster includes: the first two 
AfA studies; the other two AfA studies; two AsA studies; MEX and GIH; and two EuA 
studies (5 Clusters). The pair-wise distance between GIH-TSI or GIH-CEU is smaller 
than GIH-MEX, however, we have clusterd GIH-MEX because metasoft requires at least 
two studies entering the software. Figure 2.6 showed a one-stage and three two-stage 
clustering approaches (2 Clusters, 3 Clusters and 5 Clusters). The results suggested that 
our 2-stage approach is quite robust to the different dissimilarity thresholds where, in 
fact, the three clustering scenarios yielded the same power. We performed this additional 
simulation study only with Effect-Heterogeneity (Scenario 3).  
 
2.4.2.4 Region-wise analysis with causal variants included vs. excluded 
Because, in most genetic studies, identified associated genetic variants were not causal 
variants but in LD with those variants, we explored the surrounding region of a causal 
variant, including or excluding the causal variant, and evaluated the performance of the 
two-stage clustering approach. The overall pattern of the results was similar to what we 
had observed except in the Effect-size Heterogeneity scenario (Scenario 3). It was 
evident that the inclusion of a causal variant in the analysis suggested higher power than 
when it was excluded (Figures 2.4 and 2.5). Although less deviation in power appeared 
among the models in the African-specific scenario, the two-stage RE-HE and BE models 
were slightly more powerful compared to their counterpart one-stage approaches 
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(Figures 2.4B, 2.4C, 2.5B and 2.5C). As we previously observed, the two-stage 
approach had no benefits over the one-stage analysis when the heterogeneity in effect 
size was due to an environmental factor rather than genetic dissimilarity. 
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Table 2.5 Type I error rates of one- and two-stage clustering approaches for FE, RE, RE-HE, BE and MANTRA methods 
when sample size was equal 
  One-stage clustering approach Two-stage clustering approach 
Thresholda  
for 
FE, RE, RE-HE, 
BE 
Thresholdb  
for 
MANTRA 
FE RE RE-HE BE MANTRAc 
FE 
2-stage 
RE 
2-stage 
RE-HE 
2-stage 
BE 
2-stage 
MANTRA 
2-stage 
5e-2 logBF > 0 5.0E-02 3.9E-02 5.0E-02 5.0E-02 1.4E-01 5.0E-02 3.7E-02 4.9E-02 5.0E-02 1.3E-01 
1e-2 >1 1.0E-02 7.2E-03 1.0E-02 1.0E-02 9.2E-03 1.0E-02 7.1E-03 9.9E-03 1.0E-02 9.0E-03 
1e-3 >2 1.0E-03 6.8E-04 1.0E-03 1.0E-03 7.7E-04 1.0E-03 6.8E-04 9.9E-04 1.0E-03 7.4E-04 
1e-4 >3 1.0E-04 6.5E-05 9.7E-05 9.8E-05 6.7E-05 1.0E-04 6.5E-05 9.6E-05 9.6E-05 6.6E-05 
The thresholds for the Frequentist and Bayesian methods (a and b) are not comparable. The P-values and the Bayes’ factors are 
assessed under the null hypothesis of no association using 11,575,000 null SNPs. 
a Asymptotic thresholds for the type I error of the one-stage and the two-stage clustering approaches for the Frequentist’s 
methods (Fixed-Effects (FE), Random-Effects (RE), Random-Effects model by Han and Eskin (RE-HE) and Binary Effects 
(BE) model) 
b Thresholds for the one-stage and the two-stage clustering approaches for the Bayesian method (Meta-analysis of Transethnic 
Association studies (MANTRA) method).  
c We presented proportions that SNPs had BF greater than preselected thresholds. 
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Table 2.6 Type I error rates of both one- and two-stage clustering approaches for FE, RE, RE-HE, BE and MANTRA methods 
when sample sizes were unequal. 
  One-stage clustering approach Two-stage clustering approach 
Thresholda  
for 
FE, RE, RE-HE, 
BE 
Thresholdb  
for 
MANTRA 
FE RE RE-HE BE MANTRAc 
FE 
2-stage 
RE 
2-stage 
RE-HE 
2-stage 
BE 
2-stage 
MANTRA 
2-stage 
5e-2 logBF > 0 5.0E-02 3.8E-02 4.9E-02 5.0E-02 1.4E-01 5.0E-02 3.7E-02 4.8E-02 4.9E-02 1.4E-01 
1e-2 >1 1.0E-02 7.2E-03 9.7E-03 1.0E-02 9.1E-03 1.0E-02 6.9E-03 9.5E-03 9.9E-03 9.1E-03 
1e-3 >2 1.1E-03 7.1E-04 9.6E-04 1.0E-03 7.9E-04 1.1E-03 7.2E-04 9.6E-04 1.0E-03 7.9E-04 
1e-4 >3 9.5E-05 6.2E-05 8.4E-05 8.6E-05 6.2E-05 9.5E-05 6.7E-05 9.0E-05 8.4E-05 6.2E-05 
The sample size for the four AfA studies is 4,500 and for the other studies is 2,000. The total sample size is 30,000, same as 
the equal sample size scenarios. The thresholds for the Frequentist and Bayesian methods (a and b) are not interchangeable. The 
P-values and the Bayes’ factors are assessed under the null hypothesis of no association using 11,575,000 null SNPs.  
a Asymptotic thresholds for the type I error of the one-stage and the two-stage clustering approaches for the Frequentist’s 
methods (Fixed-Effects (FE), Random-Effects (RE), Random-Effects model by Han and Eskin (RE-HE) and Binary Effects 
(BE) model) 
b Thresholds for the one-stage and the two-stage clustering approaches for the Bayesian method (Meta-analysis of Transethnic 
Association studies (MANTRA) method).  
c We presented proportions of SNPs that had BF greater than preselected thresholds. 
 
 
  
  
 
4
2
 
Table 2.7 Empirical thresholds at the multiple testing adjusted threshold α=0.1 for both one-stage and two-stage clustering 
approaches for FE, RE, RE-HE, BE and MANTRA methods when sample size was unequal 
 One-stage clustering approach Two-stage clustering approach 
Threshold FE RE RE-HE BE MANTAR 
FE 
2-stage 
RE 
2-stage 
RE-HE 
2-stage 
BE 
2-stage 
MANTRA 
2-stage 
5e-2 5.0E-02 6.4E-02 5.1E-02 5.0E-02 0.35 5.0E-02 6.7E-02 5.2E-02 5.1E-02 0.35 
1e-2 1.0E-02 1.4E-02 1.0E-02 1.0E-02 0.96 1.0E-02 1.4E-02 1.1E-02 1.0E-02 0.96 
1e-3 9.4E-04 1.4E-03 1.0E-03 9.8E-04 1.9 9.4E-04 1.4E-03 1.0E-03 9.7E-04 1.9 
1e-4 1.0E-04 1.6E-04 1.2E-04 1.1E-04 2.8 1.0E-04 1.5E-04 1.1E-04 1.1E-04 2.8 
The sample size for the four AfA studies is 4,500 and for the other studies is 2,000. The total sample size is 30,000, same as 
the equal sample size scenarios. The left most column is the asymptotic threshold for the one-stage and the two-stage 
clustering approaches for the Fixed-Effects (FE), Random-Effects (RE), Random-Effects model by Han and Eskin (RE-HE), 
Binary Effects (BE) model and Meta-analysis of Transethnic Association studies (MANTRA) models. 
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Figure 2.2 Power comparisons for ten models (two approaches of five meta-analytic methods) for the four simulated scenarios 
when the sample size is equal (sample size=3,000 for each study and 30,000 in total, EAF=5% and α=1e-4) 
 
The four scenarios of heterogeneity of allelic effects: (A) Scenario1: Effect-size Homogeneity scenario – equal, non-zero 
allelic effects on the causal variant across the ten studies; (B) scenario 2: African-Specific Effects scenario – equal, non-zero 
allelic effects on the causal variant only in four AfA studies (AWS, LWK, MKK and YRI); (C) scenario 3: Effect-size 
Heterogeneity scenario – non-zero allelic effects in multiple studies, equal effect size among studies in the same ethnic group 
and the different effect size across the different ethnic groups (effect sizes: 0.05 for four AfA studies, 0.025 for two AsA 
studies and 0.0125 for four GEM studies); and (D) Western Exposure Effects scenario – equal, non-zero allelic effects on the 
causal variant only in the study samples living in Europe or USA (AWS, CHD, CEU and TSI).  
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Figure 2.3 Power comparisons for ten models (two approaches of five meta-analytic methods) for the African-Specific Effects 
and Effect-size Heterogeneity scenarios for unequal vs. equal sample sizes (EAF=10% and α=1e-4) 
 
For equal sample size simulation, the sample size=3,000 for each study and 30,000 in total. For unequal sample size 
simulation, the sample size in the AfA studies is increased by 1.5 times (4,500) and the sample sizes in the other ancestry 
studies are decreased by 2/3 (2,000) but the total sample size (30,000) remains the same. (A) African-Specific Effects scenario 
using unequal sample size; (B) African-Specific Effects scenario using equal sample size; (C) Effect-size Heterogeneity 
scenario using unequal sample size; (D) Effect-size Heterogeneity scenario using equal sample size.  
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Figure 2.4 Power comparisons for ten models (two approaches of five meta-analytic methods) for the four simulated scenarios 
when a causal variant is included in a region (sample size=3,000 for each study and 30,000 in total, EAF=10% and multiple 
testing adjusted threshold α=0.1) 
 
The four scenarios of heterogeneity of allelic effects: (A) Scenario1: Effect-size Homogeneity scenario; (B) scenario 2: 
African-Specific Effects scenario; (C) scenario 3: Effect-size Heterogeneity scenario; and (D) Western Exposure Effects 
scenario.  
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Figure 2.5 Power comparisons for ten models (two approaches of five meta-analytic methods) for the four simulated scenarios 
when a causal variant is not included in a region (sample size=3,000 for each study and 30,000 in total, EAF=10% and 
multiple testing adjusted threshold α=0.1) 
 
The four scenarios of heterogeneity of allelic effects: (A) Scenario1: Effect-size Homogeneity scenario; (B) scenario 2: 
African-Specific Effects scenario; (C) scenario 3: Effect-size Heterogeneity scenario; and (D) Western Exposure Effects 
scenario.
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2.5 Discussion  
Meta-analysis has been predominantly performed among European-ancestry population 
studies. However, with the use of comprehensive reference panels, the number of 
genome-wide association studies in other ethnic populations has increased. While meta-
analyzing over multiple GWAS across genetically different populations may provide an 
opportunity to enhance power by increasing sample size and to explore genetic variants 
that are either transferable across populations or unique to a certain ethnicity (Liu et al. 
2013; Liu et al. 2012), this approach also presents challenges such as potential 
heterogeneity due to differences in linkage disequilibrium, differences in underlying 
causal variants, differences in genotype platforms leading to differences in imputation 
accuracy, and possible environmental influence on genetic impacts.  
 
With the opportunities and challenges of trans-ethnic meta-analysis, we proposed a two-
stage clustering approach instead of the one-stage approach and assessed the performance 
of five meta-analytic methods that are currently available and widely being used. Our 
two-stage approach was applied to account for between-cluster heterogeneity as well as 
to bolster within-cluster homogeneity. We showed in a simulation study that our two-
stage approach can improve power in RE-HE and BE models in the presence of 
heterogeneity among multiple GWAS due to the genetic dissimilarity and can also reduce 
the computational intensity by reducing the number of studies entering the meta-analysis 
in MANTRA while maintaining similar power. (Table 2.8)  The average computational 
time was 5.9 minutes to analyze 652 variants when the number of studies included in the 
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meta-analysis in MANTRA was three in the two-stage approach while it took 10.9 
minutes for the same number of variants when the number of studies was ten in the one-
stage approach. 
 
We have examined the power and type I error of five meta-analytic methods. The type I 
error rates of all Frequentist methods were well controlled in one- and two-stage 
approaches; we lacked the ability to evaluate the type I error in the Bayesian method 
MANTRA. For a fair power comparison, we calculated empirical thresholds for all five 
methods in the two approaches and used empirical thresholds for the power computation. 
For the region-wise simulation studies, the empirical thresholds are computed using 
minimum p-value or maximum BF. The results showed that our two-stage approach has 
noticeable improvement in power especially for BE and RE-HE models and in 
computational efficiency for MANTRA compared to the crude approach when we 
assumed that heterogeneity arises from different genetic structure across diverse 
populations. Thus, the results suggested the two-stage approach may be an effective 
intermediate step in a trans-ethnic meta-analysis of GWAS that would improve power.  
 
Note that MANTRA already takes into account the estimated similarity among studies 
with respect to genetic relatedness using a Bayesian partition model. In comparison, our 
two-stage approach showed no discernable loss in power but reduced the computational 
burden by reducing the total number of studies entering MANTRA analysis. Therefore, 
the two-stage clustering approach using the prior knowledge of genetic relatedness in 
49 
 
 
terms of mean allele frequency improves power when the difference between studies is 
due to genetic dissimilarity, and enhances the computational efficiency by diminishing 
the computation burden for the Bayesian method MANTRA.   
 
We acknowledge that there may be limitations in our two-stage approach. Because we 
use genetic distance as prior information to cluster, the cluster classification is pre-fixed 
and is not updated using other information such as allelic effect estimates as in 
MANTRA. Further, the fixed threshold applied to the genetic distance in the dendrogram 
for clustering is rather subjective and arbitrary, and may be prone to mis-clustering of 
genetically heterogeneous studies. However, as shown in Figure 2.6, the two-stage 
approach is robust to mis-clustering by taking a sub-optimal dissimilarity value for the 
threshold. In practice, clustering using the prior knowledge of ancestry of study samples 
is recommended. Alternatively, a data-driven approach can be used to find an optimal 
threshold for clustering. Assessing the power in the region-wise analysis using the 
empirical threshold computed by minimum p-value or maximum BF in a region would be 
more precise if a larger number of replicates were evaluated. Lastly, when heterogeneity 
arises from environmental factors rather than genetic dissimilarity, our two-stage 
approach tends to lose power due to incorrect clustering. In such a case, further 
refinement of current approaches need to be developed, such as introducing another layer 
of clustering or treating those environmental factors as random effects, to properly 
account for the multiple sources of the heterogeneity and to retain good power. 
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In conclusion, with the growing interest and availability of GWAS results from diverse 
populations, the use of appropriate strategies and analytic tools in trans-ethnic meta-
analysis will be crucial. In such meta-analyses, our two-stage approach accounts for 
potential heterogeneity due to genetic dissimilarity and therefore boosts power to detect 
genetic signals. In addition, our simulation study shows that the conventional FE and RE 
models may not be suitable for the trans-ethnic meta-analysis in GWAS because the 
assumption of the FE model may be violated and because the RE model may be too 
conservative. In that case, the three recently developed methods have great advantages 
over the conventional methods. They are robust and more powerful especially when the 
studies in the meta-analysis are potentially heterogeneous. However, inappropriate and 
incorrect clustering of studies can result in power loss. Therefore the use of the three 
robust recent meta-analytic methods in the appropriate two-stage clustering strategy may 
enhance the ability to uncover and understand genetic signals contributing to human 
complex disease.  
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Table 2.8 Average computational time (in minutes) for MANTRA using the one-stage 
(10 Clusters) and three two-stage clustering (2 Clusters, 3 Clusters, 5 Clusters) 
approaches when sample size was equal 
 
One-stage 
clustering 
approach 
Two-stage clustering approach 
(In minutes) 10 Clusters 2 Clusters 3 Clusters 5 Clusters 
652 SNPs 10.9 5.0 5.9 7.3 
11,575 SNPs 192.3 89.5 104.4 128.8 
We used Intel®  Xeon®  Processor E5-2650 v2 (20M Cache, 2.60 GHz) for this 
comparative computational time analysis. 
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Figure 2.6 Sensitivity analysis of the two-stage approach by varying the threshold of 
dissimilarity resulting in a different number of clusters in addition to the one-stage (10 
studies) and the initial two-stage approach (3 Clusters) 
 
In the 2 Clusters scenario, we included four African studies in one cluster and the rest of 
the studies in the other cluster. In the 5 Clusters scenario, we had five clusters with 
studies in each cluster as follows: the first two African studies from Figure 2.1; the other 
two African studies; the two Asian studies; MEX and GIH; and the two EuA studies. In 
total, twenty models (four clustering approaches of five meta-analytic methods) were 
presented with Effect-Heterogeneity (Scenario 3) simulation setting when the sample size 
is equal (sample size=3,000 for each study and 30,000 in total, α=1e-4). 
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Chapter 3 Statistical Model with Multiple Random Effects to Account for 
Heterogeneity  
 
3.1 Introduction  
The popularity of meta-analysis has consistently grown in the fields of clinical trials, 
epidemiological studies, statistical genetics, and many other areas of medical research 
(Lee, Bausell, and Berman 2001; DerSimonian and Laird 2015; Sutton and Higgins 2008; 
Zeggini and Ioannidis 2009). Meta-analysis refers to a statistical approach to aggregate 
evidence from multiple independent studies to specifically address a common hypothesis 
and gain a better understanding of treatment effects. The sample size of a single 
individual study is often too small to detect and provide a reliable estimate of a treatment 
effect. The primary advantage of meta-analysis is to increase power by increasing sample 
size and to derive a robust pooled estimate closest to the true but unknown parameters of 
interest. Ideally, the underlying effect sizes in each participating study are the same, and 
the variation of the study-specific effect estimates is due to sampling variation alone. 
However, such a simple setting is not always the case in reality and variation due to 
multiple sources other than chance may contribute to the complex setting of 
heterogeneous studies. The goal of this paper is to develop a statistical framework for 
meta-analysis to account for potential heterogeneity from multiple sources which may be 
quantified by cohort-specific characteristics.  
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Heterogeneity across participating studies may be explored via meta-analysis. There has 
been increasing interest in determining which study covariates may influence on the main 
effects of interest. In clinical and epidemiological studies, one may assume that factors 
such as geographical location, drug dosage or duration of treatment might change the 
effects of treatment and cause heterogeneity in effect size across studies (Simmonds and 
Higgins 2007; Sterne et al. 2002; Abrams, Gillies, and Lambert 2005; Colditz et al. 
1994). Heterogeneity can also arise from the use of different techniques of measuring 
outcomes and study designs (S G Thompson 1994; Abrams, Gillies, and Lambert 2005; 
Simon G. Thompson and Sharp 1999). In statistical genetics, differences in genetic 
architecture such as linkage disequilibrium (LD), differences in underlying functional 
variants and differences in allele frequencies of functional variants can result in 
heterogeneity in the effect sizes in the meta-analysis of GWAS (Morris 2011; Y. Li and 
Keating 2014; Fu, Festen, and Wijmenga 2011). Different genotyping quality and 
imputation accuracy can also contribute to heterogeneity across studies (de Bakker et al. 
2008; Zaitlen and Eskin 2010). Furthermore, non-genetic exposures such as different 
level of environmental exposure or life style may also differ across study cohorts, and 
may affect effect size. Thus, clinical, methodological, and/or genetic differences may 
lead to statistical heterogeneity that can be accounted for using an appropriate statistical 
model.  
 
Conventional meta-analytic methods, inverse-variance-weighted fixed-effects (FE) and 
random-effects (RE) models, have widely been used in the meta-analysis. The FE model 
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provides a weighted average of effect estimates under the  assumption of that the 
underlying effects are the same across studies (Fleiss 1993; Hedges and Olkin 1985). The 
inverse of the variance of the estimate can be used as a weight to account for difference 
in sample size, so a larger study is given greater weight compared to a smaller study. In 
the presence of heterogeneity, the FE model is inappropriate because it underestimates 
the standard error of the effect estimate. We can formally test for homogeneity of effect 
sizes using Cochran’s Q statistic (Cochran 1952). We can use the I2 statistic (Higgins and 
Thompson 2002) to quantify how much of the total variability is due to heterogeneity in 
the effect sizes. Higgins and Thompson (2002) suggest that a value of I2 greater than 50% 
might indicate substantial heterogeneity among effect sizes and that such heterogeneity 
might influence the interpretation of the meta-analysis that we should not ignore. In the 
presence of heterogeneity, the use of a RE model is more appropriate. The RE model 
properly estimates the standard error and yields more accurate confidence intervals by 
incorporating between-study variability into the weights (DerSimonian and Laird 1986; 
Hedges and Olkin 1985; Fleiss 1993). However, the conventional RE model  is  less 
powerful than the FE model even in the presence of heterogeneity (B. Han and Eskin 
2011) because of its conservative assumption that the between-study variance is not zero 
under the null hypothesis. Therefore, the conventional RE model is not optimal for 
testing pooled effects associated with an outcome via meta-analysis and some 
methodological development is needed to improve power. 
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One alternative to the conventional meta-analytic models is meta-regression. Meta-
regression is a regression approach in which effect size is used as the dependent variable 
and study-level covariate measures as explanatory variables to examine the impact of 
study-level characteristics on treatment effects in clinical trials (Simmonds and Higgins 
2007; Abrams, Gillies, and Lambert 2005; Greenland 1987). Similar to the conventional 
FE and RE models, FE- or RE-meta-regression (FE-metaReg / RE-metaReg) can be used 
depending on the assumption of homogeneity of effect size. Under the FE-metaReg, for a 
set of covariate values, we assume that the true underlying effect among studies is the 
same. Under the RE-metaReg, for any set of covariate values, we assume that the true 
effects may vary across studies and may follow a certain distribution. When data are 
pulled from the literature or from studies conducted by different investigators, it is 
plausible to assume that the covariates in a model would explain some, but not all, of the 
true heterogeneity in effect sizes across studies, and any remaining heterogeneity should 
be acknowledged in the analysis (S. Thompson and Higgins 2002; Viechtbauer 2007). In 
this case, the RE-metaReg is more appropriate to use because it properly accounts for the 
remaining heterogeneity that has not been explained by the covariates in the model. 
However, both metaReg models test the null hypothesis of no linear relationship between 
the covariates and the effect size. In reality, this linearity assumption is questionable. If 
the true relationship is non-linear between the covariates and the effect size, it is hard to 
determine the true relationship with the small number of studies in a typical meta-
analysis. In this case, the use of the metaReg models would violate the linearity 
assumptions.  
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Another random-effects meta-analytic approach proposed by Han and Eskin (RE-HE) (B. 
Han and Eskin 2011) improves power compared to the conventional FE and RE models 
especially in the presence of heterogeneity. The null hypothesis for the RE-HE approach 
is that the mean effect is 0 and there is no heterogeneity.  This is in contrast to the 
conventional RE model, which tests the null hypothesis that the mean effect is 0 but 
allows for heterogeneity. The alternative for both models is the same – that the mean 
effect is not 0, or that there is heterogeneity. The RE-HE model assumes a single 
aggregated between-study heterogeneity that blends all potential sources.  However, the 
assumption of a single source of heterogeneity may not be realistic and heterogeneity 
may arise from multiple sources as described earlier.  
 
In this chapter, we incorporate the idea of testing the between-study variances of RE-HE 
approach under meta-regression framework and propose a new statistical model that 
accommodates multiple sources of potential heterogeneity which can be measured by 
study-level characteristics.  
 
We develop our method in section 2. In order to account for different sources of 
heterogeneity, we assume that study characteristics are pertinent to heterogeneity in the 
effect size and treat them as random effects. We use a linear mixed effect model to 
incorporate the multiple random effects and implement the likelihood ratio test (LRT) to 
perform hypothesis testing. In section 3, we demonstrate the performance of our proposed 
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approach in extensive simulations in terms of type I error and power, and compare the 
approach to other existing meta-analytic methods including FE, RE, RE-HE and FE-/RE-
metaReg over a range of heterogeneity scenarios. We then apply our new model in 
section 4 to meta-analyze 15 GWAS studies (N=36,846) of fasting insulin from the Meta-
Analyses of Glucose- and Insulin- related traits Consortium (MAGIC) to identify variants 
associated with fasting insulin considering study-specific mean age and BMI as random 
effects. We conclude this article with a discussion in section 5.  
 
3.2 Methods 
3.2.1 Linear Mixed Effects Model with Multiple Random Effects 
3.2.1.1 Notations and Assumptions 
We first define notation and assumptions and then derive a test statistic that accounts for 
heterogeneity from multiple sources. Suppose we would like to determine the association 
between a treatment and an outcome of interest by synthesizing the association findings 
from K studies. For each of these K studies, summary statistics measuring the association 
with the outcome of interest are available and study-level characteristics are measured. 
We assume that the treatment effect for each study may vary according to the study 
characteristics and thus has potential heterogeneity. We treat these study-level covariates 
as random effects to take the heterogeneity into consideration in the statistical modeling 
using a linear mixed effects model as follows: 
 
𝐛 = 𝜷 + 𝒁𝒗 + 𝒆 , 
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where 𝒃 is a K-dimensional vector of observed effect estimates from K studies and 𝜷 is 
an unknown true effect size. 𝒁 is a matrix of size K by r for the r study characteristics and 
𝒗 is an r-dimensional vector of unknown random effects. We assume the random effects, 
𝒗, and the residual errors, 𝒆, are uncorrelated and follow multivariate normal distributions 
with mean 0 and covariance matrices, 𝜮𝑣 and 𝑹, respectively. That is,  
 
𝒗 ~ 𝑵(𝟎, 𝜮𝑣), 
𝒆 ~ 𝑵(𝟎,𝑹). 
The covariance matrix for the random effects is 𝜮𝑣 = 𝑣𝑎𝑟[𝒗] = [
𝜏1
2 ⋯ 𝜏1𝑟
⋮ ⋱ ⋮
𝜏𝑟1 ⋯ 𝜏𝑟
2
]. We 
assume the random effects are uncorrelated and therefore the off-diagonal elements of 
 𝜮𝑣 are equal to zero (𝜏𝑖𝑗 = 𝜏𝑗𝑖 = 0, for all 𝑖 ≠ 𝑗). The covariance matrix for the residual 
errors is 𝑹 = [
𝜎1
2 ⋯ 0
⋮ ⋱ ⋮
0 ⋯ 𝜎𝐾
2
]. We make the conventional assumption that the elements of 
the within-study covariance matrix R are known values (Higgins and Thompson 2002). 
The parameters of interest are 𝜽 = (𝛽, 𝜏1
2, … , 𝜏𝑟
2). Under this setting, we would like to 
establish a (log-)likelihood ratio test (LRT) statistic to test H0:  𝜽 ∈ 𝚯𝟎 vs. H1:  𝜽 ∈ 𝚯𝟏, 
where 𝚯𝟎 = {𝜽𝟎: 𝛽 = 0,  𝜏1
2 = 0,… ,  𝜏𝑟
2 = 0} and 𝚯𝟏 = {𝜽: 𝛽 ≠ 0,  𝜏1
2 > 0,… , 𝑜𝑟 𝜏𝑟
2 >
0}. In our composite hypotheses, we assume no association (𝛽 = 0) and no 
heterogeneity (𝜏1
2 = 0,… , 𝜏𝑟
2 = 0) under the null hypothesis (B. Han and Eskin 2011; 
Higgins, Thompson, and Spiegelhalter 2009; Lebrec, Stijnen, and van Houwelingen 
60 
 
 
2010). Under these assumptions, the marginal distribution of 𝒃 follows a multivariate 
normal distribution with mean E[𝐛] = 𝜷 and covariance matrix 𝑉𝑎𝑟[𝐛] = 𝑾, i.e. 
𝒃 ~ 𝑵(𝜷,   𝑾), 
where 𝑾 = 𝒁𝜮𝒗𝒁
′ + 𝑹.  
 
3.2.1.2 Likelihood Ratio Test Statistic 
Using this marginal distribution of 𝒃, we can obtain the likelihoods (L) under the null 𝜽 ∈
𝚯𝟎 and the union of 𝜽 ∈ 𝜣𝟎 ∪ 𝜣𝟏 as follows: 
 
𝐿𝜃0 =
1
(√2𝜋)𝑘
|𝑹|−
𝟏
𝟐 ∗ 𝑒𝑥𝑝 (−
𝟏
𝟐
𝒃′𝑹−𝟏𝒃), 
𝐿𝜃 =
1
(√2𝜋)𝑘
|𝑾|−
𝟏
𝟐 ∗ 𝑒𝑥𝑝 (−
𝟏
𝟐
(𝒃 − 𝜷)′𝑾−𝟏(𝒃 − 𝜷)). 
 
We are interested in estimating the parameters that maximize the likelihood under the 
alternative hypothesis. There is a closed-form solution for the maximum likelihood 
estimator of the true effect size 𝛽; however, there is no closed-form for the variances of 
the random effects 𝜏𝑗
2, for 𝑗 = 1,… , 𝑟 (See derivations in Appendix A). Hence we use a 
Nelder-Mead optimization algorithm implemented in dfoptim R package (Varadhan and 
Borchers 2011; Kelley 1999) to numerically obtain the parameter estimates which 
optimize the likelihood. With these estimates, the LRT statistic can be expressed as 
follows: 
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𝑇 = −2ln (
𝐿𝜃0
𝐿𝜃
) = ( 𝑙𝑛|𝑹| + 𝒃′𝑹−1𝒃) − (𝑙𝑛|?̂?| + (𝒃 − ?̂?)
′
?̂?−1(𝒃 − ?̂?)),               (1) 
 
where ?̂? =  𝒁?̂?𝒗𝒁
′ + 𝑹, ?̂?𝒗 = diag(?̂?1
2, ?̂?2
2, … , ?̂?𝑟
2), 𝑹 = 𝑑𝑖𝑎𝑔(𝜎1
2, 𝜎2
2, … , 𝜎𝐾
2), ?̂? and 
?̂?𝑗
2, for 𝑗 = 1,… , 𝑟, are the estimates from the numerical approach (Kelley 1999; 
Varadhan and Borchers 2011).  
 
3.2.2 Asymptotic Distribution 
The statistical significance of the test statistic can be assessed using the asymptotic 
distribution of the LRT statistic 𝑇. 𝛽 is unrestricted but 𝜏𝑗
2, for 𝑗 = 1,… , 𝑟, are the 
boundary parameters restricted to be non-negative. Hence 𝛽 corresponds to a 𝜒1
2 
distribution and each of 𝜏𝑗
2, for 𝑗 = 1,… , 𝑟, to a 50:50 mixture of 𝜒0
2 and 𝜒1
2 distributions 
(Self and Liang 1987). The asymptotic distribution of the test statistic 𝑇 is determined by 
the number of random effects we put in a model. For example, if we assume one random 
effect in the model (j=1) the test statistic 𝑇 would asymptotically follow a 50:50 mixture 
of 𝜒1
2 and 𝜒2
2 distributions (B. Han and Eskin 2011; Self and Liang 1987). When we 
assume two random effects (j=2) with no correlation, the test statistic would 
asymptotically follow a mixture of three Chi-square distributions, 𝜒1
2, 𝜒2
2 and 𝜒3
2, with 
mixing probability 𝑝 =
1
4
 (Self and Liang 1987). Therefore, the resulting distribution for 
the test statistic 𝑇 with two random effects asymptotically follows a  
1
4
𝜒1
2 +
1
2
𝜒2
2 +
1
4
𝜒3
2. 
62 
 
 
We can easily expand this for more than two random effects under the assumption of no 
pair-wise correlation among the random effects. The general form of the asymptotic 
distribution of the LRT statistic, testing 𝐻0: 𝛽 = 0, 𝜏1
2 = 0,… , 𝜏𝑟
2 = 0,  can be expressed 
as a binomial function with a mixing probability 𝑝 = (
1
2
)
𝑟
as follows  
 ∑(
𝑟
𝑗)
𝑟
𝑗=0
(
1
2
)
𝑟
𝜒𝑗+1
2  , 
where r indicates the number of random effects and the mixing probability assuming the 
random effects are pairwise uncorrelated. For the one random effects case, the mixing 
probability is 𝑝 =
1
2
 and the distribution of the test statistic, testing 𝐻0: 𝛽 = 0,  𝜏
2 = 0, 
would be ∑
1
2
1
𝑗=0 𝜒𝑗+1
2 . If we are testing two random effects along with the main effect, 
𝐻0: 𝛽 = 0,  𝜏1
2 = 0, 𝜏2
2 = 0, the distribution would be ∑ (
2
𝑗
)2𝑗=0 (
1
2
)
2
𝜒𝑗+1
2 . 
 
3.2.3 Corrected Null Distribution 
Although we derive the asymptotic distribution, a large number of studies are required to 
reach the asymptotic distribution, and the number of studies in a meta-analysis is 
typically small in practice.  If the asymptotic distribution is not achieved, p-values tend to 
be overly conservative (B. Han and Eskin 2011; B. Han, Kang, and Eskin 2009). 
There are several ways to better approximate the distribution of the test statistic 𝑇 for 
limited sample sizes. Han and Eskin (2011) evaluated p-values by tabulated values they 
calculated for each possible number of studies from 2 to 50 (B. Han and Eskin 2011). 
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Han and Pan (2010) re-calibrated the null distribution of their test statistic so that the type 
I error rate would be well controlled (F. Han and Pan 2010). Han and Pan empirically 
evaluated scaling and shifting parameters of their asymptotic distribution and used the 
scaled-shifted null distribution to obtain a p-value. 
 
We take a similar approach as described in the Han and Pan (2010) to find a “corrected” 
null distribution that would correct the conservativeness of the asymptotic distribution. 
(See the type I error rates using the asymptotic distribution in Table 3.1.) Here we 
consider the case of two random effects. Because we know that the asymptotic 
distribution of our test statistic for two random effects follows the mixture of 𝜒𝑔
2 
with 𝑔 = 1, 2 and 3 degrees of freedom, we compare several candidate distributions with 
𝑔 ≤ 3 from the three general forms: 
 
(a) 𝑎 𝜒𝑔
2 + 𝑏 where 𝑔=degree(s) of freedom of 1, 2, or 3. 
(b) 𝑎 𝜒𝑔1
2 + 𝑏 𝜒𝑔2
2 + 𝑐 where 𝑔1 and 𝑔2 are a combination of degree(s) of freedom of 
1, 2, and 3 such that  𝑔1=1 or 2, and 𝑔2=2 or 3. 
(c) 𝑎 ∗ 𝜒1
2 + 𝑏 ∗ 𝜒2
2 + 𝑐 ∗ 𝜒3
2.  
 
We want to estimate the scaled-shifted parameters, a, b and/or c, and compare type I 
errors evaluated from of the candidate distributions. The proposed implementation to 
estimate the scaled-shifted parameters for each candidate distribution is as follows:  
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(1) Generate summary measures, 𝜎𝑖
2 and 𝑏𝑖, for the 𝑖
th study, where 𝑖 = 1, … , 𝐾, 
using  𝜎𝑖
2~𝜒1
2 and 𝑏𝑖~𝑁(0, 𝜎𝑖
2). 
(2) Numerically estimate the parameters 𝛽, 𝜏1
2 and 𝜏2
2, which optimize the likelihood 
ratio using a Nelder-Mead optimization algorithm implemented in dfoptim R 
package (Varadhan and Borchers 2011; Kelley 1999).  
(3) Compute the null LRT statistic, 𝐿𝑅𝑇𝑒𝑚𝑝, for N=50 as shown in the equation 1 in 
3.2.1.2 using the generated summary measures in (1) and parameter estimates in 
(2).  
(4) Repeat the process 𝐵 times, giving 𝐵 test statistics 𝐿𝑅𝑇𝑒𝑚𝑝  
(5) Generate random numbers from 𝜒1
2, 𝜒2
2 and 𝜒3
2 and compare with the 𝐵 test 
statistics 𝐿𝑅𝑇𝑒𝑚𝑝 in (4) to estimate the scaled-shifted parameters (a, b and/or c) 
using a regression, method of moments (F. Han and Pan 2010; S. Li and Cui 
2012), or a numerical method (Turlach).  
 
Once the scaled-shifted parameters are estimated, we construct an empirical distribution 
and calculate p-values of the 𝐿𝑅𝑇𝑜𝑏𝑠 statistics by calculating the proportion of the 𝐵 test 
statistics 𝐿𝑅𝑇𝑒𝑚𝑝 that are greater than or equal to 𝐿𝑅𝑇𝑜𝑏𝑠. We evaluate type I error rates 
by calculating the proportion of the empirical p-values that passes a pre-specified 𝛼 level 
considering four study covariate combinations; continuous, dichotomous, proportion 
variables, and a combination of continuous and dichotomous variables. So we compare 
the type I error rates for the four study covariates among the candidate distributions and 
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choose one that corrects the conservativeness of the asymptotic distribution with well-
controlled type I error rates.  
 
After carefully following these steps and comparing the candidate distributions 
(Appendix B), the following mixture distribution, 𝑎 𝜒1
2 + 𝑏 𝜒22
2 + 𝑐, shows anti-
conservative but well-controlled type I error rates and therefore is used as our “corrected” 
null distribution. The scaled-shifted parameters 𝑎, 𝑏, and 𝑐 are estimated according to the 
study covariates following the proposed steps (1)-(4).  
 
 
3.3 Simulation Study  
3.3.1 Study Design of Simulation 
3.3.1.1 General Setting 
We conducted a simulation study to evaluate the type I error and power of our test 
statistic T in the presence or absence of random effects. For simplicity and without loss of 
generality, we considered the situation with two random effects for this simulation study. 
We compared the performance of our approach to the conventional FE and RE models, 
Han and Eskin’s modified random-effects, RE-HE, and FE-/RE-meta-regression 
(metaReg) methods. We considered three scenarios where both of the random effects can 
be represented by proportion, continuous, or dichotomous characteristics, and an 
additional scenario having different types of study-level covariates where the two 
covariates were a combination continuous and dichotomous variables.  
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3.3.1.2 Type I error Simulation 
We evaluated the type I error under the null hypothesis of no association and no 
heterogeneity by setting all three parameters to zero, (𝐻0: 𝛽 = 0, 𝜏1
2 = 0, and 𝜏2
2 = 0). 
We first generated within-study variances, 𝜎𝑖
2, from a  𝜒1
2 distribution and exclude 
extreme values that are less than 10% or greater than 90% percentiles of the distribution. 
Among remaining values, we randomly selected K values for within-study 
variances, 𝜎𝑖
2, for 𝑖 = 1,… , 𝐾, and assigned them to studies as the elements of the 
diagonal covariance matrix R. We generated observed effect estimates, 𝒃, from a 
multivariate normal distribution 𝑵(𝟎,𝑹). Then we numerically estimated parameters, 
𝛽, 𝜏1
2 and 𝜏2
2 from these data, and computed a null LRT statistic. We vary the number of 
studies, 𝐾, with K= 10 , 20, 50 and 100, to investigate the effect of the number of studies 
on the meta-analysis results. 
 
We can evaluate our test statistic and corresponding p-value from the asymptotic 
distribution. However, given the small number of studies, the asymptotic distribution 
yielded overly conservative type I error rates in our preliminary simulation results (Table 
3.1) and a corrected null distribution was needed. Thus we established a corrected null 
distribution as described earlier (in 3.2.3) and computed the p-value from the corrected 
null distribution. We evaluated the empirical type I error rates at different significance 
levels 𝛼 by computing the proportion of p-values that are less than or equal to the 
corresponding 𝛼 level. We repeated this procedure for each four study-characteristic 
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scenarios where the characteristics of the random variables are continuous, dichotomous, 
proportion covariates, and a combination of continuous and dichotomous variables. 
 
3.3.1.3 Power Simulation 
We evaluated power in three heterogeneity scenarios. In scenario 1, we considered a 
fixed effects (i.e., no heterogeneity, 𝛽 ≠ 0, 𝜏1
2 = 0, 𝜏2
2 = 0) scenario, in which we 
assumed that the underlying true effect was consistent across studies and so presented no 
heterogeneity. In scenario 2, we considered situations where main effects and two 
random effects were present and non-zero among the studies (i.e. 𝛽 ≠ 0, 𝜏1
2 ≠ 0, 𝜏2
2 ≠ 0). 
In scenario 3, we considered the situation where main effects and only one random 
effects were non-zero (i.e. 𝛽 ≠ 0, 𝜏1
2 ≠ 0, 𝜏2
2 = 0). The within-study variances, R, were 
generated and assigned to the studies in the same way as in the type I error simulation. 
However, we simulated the observed values of effect estimates, b, from a multivariate 
normal distribution 𝑀𝑁(𝜷,𝑾), where 𝜷 is a vector of the pre-specified true effect sizes, 
𝑾 = 𝒁𝜮𝒗𝒁
′ + 𝑹 with 𝜮𝒗 = [
𝜏1
2 0
0 𝜏2
2]. 𝒁 is a 𝐾 by 𝑟 matrix containing study-level 
covariate measures as elements, where 𝐾 is the number of studies and 𝑟 is the number of 
unknown random effects.  
 
In all simulation scenarios, we considered two random effects (𝑟 = 2) and the study-
level covariates were generated as follows. For the continuous variables, the values were 
generated from a standard normal distribution, 𝑁(0, 1). When the variables were 
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dichotomous, we generated from a binomial distribution with a success probability of 𝑝, 
𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝 = 0.5). We also varied the probability 𝑝 and showed results in Appendix 
C.2. If the variables were proportions, we generated from a uniform distribution between 
0 and 1, 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0,1). To evaluate power, we varied the values of four parameters; the 
effect size, 𝛽 from 0.01 to 0.05, 0.1, 0.15 and 0.2, the number of studies, 𝐾, from 10, 20, 
50 and 100, and the two between-study variances, 𝜏1
2 and 𝜏2
2, from 0.05, 0.1, 0.2, 0.5, 1 
and 2 to reflect the level of heterogeneity. In order to investigate the effect of each of the 
four parameters (𝛽, 𝐾, 𝜏1
2 and 𝜏2
2) on power, we changed the value of one parameter while 
keeping the other parameters constant. 
 
3.3.2 Simulation Study Results 
3.3.2.1 Type I Error Simulations 
Table 3.1 shows type I error rates of our LRT approach using both asymptotic and 
empirical distributions at different α levels in four different settings of study 
characteristics. The results suggested that the type I error rates from the asymptotic 
distribution were overly conservative. In contrast, our corrected distribution retained the 
correct type I error rates regardless of the number of studies and the study characteristics. 
Therefore, in subsequent real data analysis we used the corrected distribution to evaluate 
p-values. The type I error rates of the FE, RE, RE-HE and FE-/RE-metaReg at α=0.01 
were shown in Table 3.2. The p-values for RE-HE model were computed using metasoft 
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(B. Han and Eskin 2011). All models had well controlled type I error rates even though 
RE, RE-HE and RE-metaReg were somewhat conservative.  
 
3.3.2.2 Power Simulations 
Power of our LRT, FE, RE, RE-HE, and FE-/RE-metaReg models for the three 
heterogeneity scenarios were evaluated. We computed p-values of our LRT using both 
corrected (cLRT) and asymptotic (aLRT) distributions. In all scenarios, two study-level 
covariates were included as the sources of heterogeneity.  
 
Figure 3.1 shows the power results of the scenario 1 where we assumed no 
heterogeneity. Power increased in all models as the number of studies or the effect size 
increased. FE was the most powerful when there was no heterogeneity in effect size 
followed by cLRT, RE-HE and RE in all four different study characteristic scenarios. 
aLRT and FE-/RE-metaReg were less powerful than RE.  
 
Figure 3.2 shows the power results under the scenario 2 where we introduced 
heterogeneity by two non-zero random effects. In this scenario, each method performed 
slightly differently according the different study covariates. Overall, power improved in 
all models as the number of studies, the effect size, or the size of between-study variances 
increased. When the covariates were continuous, cLRT, RE-HE, FE-metaReg and aLRT 
performed fairly well, followed by RE-metaReg, FE and RE. When the covariates were a 
combination of the continuous and dichotomous, FE and RE models remained less 
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powerful but the power of RE-metaReg became similar to aLRT and RE-HE while cLRT 
and FE-metaReg remained most powerful. When the covariates were dichotomous or a 
proportion, the difference in power among the models became less distinctive, because in 
this scenario, the between-study variance pertinent to the study-level covariates became 
relatively small. In the dichotomous and proportion scenarios, the cLRT remained most 
powerful among the models followed by RE-HE and FE-metaReg in general, and aLRT, 
RE-metaReg and FE models were not far behind even though there were some 
fluctuations among the remaining models in terms of power.  
 
The conventional FE and RE appeared less powerful than the other models as 
heterogeneity was introduced, especially when the study covariates were continuous or a 
combination of continuous and dichotomous. The RE model was least powerful even 
when heterogeneity was present and even had decreased power in the continuous 
covariates scenario as the between-study variances increased, as shown in Figure 3.2C. 
This phenomenon was previously observed (B. Han and Eskin 2011; Hong et al.). The 
RE model assumes non-zero between-study variance under the null hypothesis.  As a 
result, there is no gain in power in the RE model with larger between-study variances.  
 
We additionally show the scenario of a single non-zero random effect in Figure 3.3. 
Here, the overall trend of power results appeared similar to that of scenario 2. The cLRT 
was consistently the most powerful approach among the models when only one of the 
two random effects was non-zero.  
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Table 3.1 Type I error rates of our approach at different α levels using the asymptotic distribution with fifty studies and the 
corrected distribution 
  Asymptotic Corrected 
α levels 
Study 
Characteristics a 
Nb =50 N=10 20 50 100 
α=0.01 
CONT+CONT 0.0045 0.0100 0.0104 0.0102 0.0103 
DICH+DICH 0.0035 0.0099 0.0102 0.0094 0.0100 
PROP+PROP 0.0028 0.0094 0.0102 0.0097 0.0100 
CONT+DICH 0.0040 0.0102 0.0101 0.0105 0.0108 
α=0.001 
CONT+CONT 0.0004 0.0008 0.0009 0.0009 0.0007 
DICH+DICH 0.0003 0.0009 0.0009 0.0009 0.0008 
PROP+PROP 0.0003 0.0010 0.0011 0.0009 0.0009 
CONT+DICH 0.0002 0.0009 0.0010 0.0008 0.0009 
We vary the number of studies from 10 to 20, 50 and 100. Continuous, dichotomous, proportion and a combination of 
continuous and dichotomous covariates are used for the sources of heterogeneity. The p-values are assessed under the null 
hypothesis of no association and no heterogeneity using 100,000 replicates. 
a Types of study characteristics as the sources of heterogeneity; CONT-Continuous, DICH-dichotomous, PROP-proportion, 
CONT+DICH-a combination of continuous and dichotomous covariates. 
b The number of studies in the simulation study.  
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Table 3.2 Type I error rates of FE, RE, RE-HE and FE-meta-regression at α=0.01 
α levels 
Different 
Models a 
N=10 20 50 100 
α=0.01 
FE 0.0101 0.0101 0.0098 0.0101 
RE 0.0065 0.0067 0.0071 0.0074 
RE-HE 0.0088 0.0085 0.0086 0.0072 
FE-
metaRreg 
CONT b 0.0101 0.0103 0.0103 0.0100 
DICH b 0.0103 0.0102 0.0101 0.0100 
PROP b 0.0098 0.0097 0.0100 0.0098 
CONT+DICH b 0.0099 0.0097 0.0102 0.0094 
 
RE-
metaReg 
CONT b 0.0069 0.0073 0.0077 0.0078 
 DICH b 0.0071 0.0074 0.0075 0.0076 
 PROP b 0.0067 0.0065 0.0074 0.0074 
 CONT+DICH b 0.0068 0.0068 0.0079 0.0070 
We vary the number of studies from 10 to 20, 50 and 100. Continuous, dichotomous, proportion and a combination of 
continuous and dichotomous covariates are used for the sources of heterogeneity. The p-values are assessed under the null 
hypothesis of no association and no heterogeneity using 100,000 replicates. 
a Different models used; FE, Fixed effects; RE, Random effects; RE-HE, Han and Eskin random effects; FE-metaReg, Fixed 
effects meta-regression; RE-metaReg, Random effects meta-regression models.  
b Types of study characteristics used only for the meta-regression model; CONT-Continuous, DICH-dichotomous, PROP-
proportion, CONT+DICH-a combination of continuous and dichotomous covariates.
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Figure 3.1 Power results of Scenario1: Effect-size Homogeneity scenario where random 
effects are zero 
 
Continuous, dichotomous, proportion and a combination of continuous and dichotomous 
covariates are used for the sources of heterogeneity.  
Five meta-analytic methods are compared; our new LRT model using Corrected (C) and 
Asymptotic (A) distributions, modified RE by Han and Eskin (H), FE(M)-/RE(m)-meta-
regression global test, FE (F) and RE (R) models.   
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Figure 3.2 Power results of Scenario 2: Effect-size Heterogeneity scenario with two non-
zero random effects 
 
Continuous, dichotomous, proportion and a combination of continuous and dichotomous 
covariates are used for the sources of heterogeneity.  
Five meta-analytic methods are compared; our new LRT model using Corrected (C) and 
Asymptotic (A) distributions, modified RE by Han and Eskin (H), FE(M)-/RE(m)-meta-
regression global test, FE (F) and RE (R) models.   
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Figure 3.3 Power results of Scenario 3: Effect-size Heterogeneity scenario with one 
random effect where only one random effect is present and non-zero 
 
Continuous, dichotomous, proportion and a combination of continuous and dichotomous 
covariates are used for the sources of heterogeneity.  
Five meta-analytic methods are compared; our new LRT model using Corrected (C) and 
Asymptotic (A) distributions, modified RE by Han and Eskin (H), FE(M)-/RE(m)-meta-
regression global test, FE (F) and RE (R) models.   
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3.4 Application to Meta-Analysis of GWAS on Fasting Insulin  
3.4.1 Background 
The prevalence and burden of type 2 diabetes (T2D) has increased over time (Cowie et al. 
2009). T2D accounts for 90-95% of all diagnosed diabetic cases, and its complications 
are major risk factors for morbidity and mortality (Engelgau 2004). In addition, T2D 
usually begins with insulin resistance in which insulin that is produced in the body is not 
properly used. As a result, glucose remains in the blood instead of being absorbed by 
cells and blood glucose level rises above the normal range. Hyperglycemia, an excess of 
glucose in the bloodstream, may involve complications, including visual impairment, 
kidney failure, lower-extremity disease, and increased risk of mortality (Engelgau 2004). 
There is great interest in explaining how genes confer genetic risk in different 
environmental contexts and in better understanding the etiology of T2D (Permutt, 
Wasson, and Cox 2005).  
 
3.4.2 Statistical Analysis 
We assembled fifteen cohorts from the Meta-Analyses of Glucose- and Insulin-related 
traits Consortium (MAGIC), totaling up to 36,846 non-diabetic individuals of European 
ancestry from fifteen studies. These studies were part of a previous study that performed 
genome-wide joint meta-analysis analysis looking for genetic variants associated with 
glycemic traits simultaneously adjusting for body mass index (BMI) and allowing for 
genetic interaction with BMI (Manning et al. 2012). Specifically, each participating 
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cohort provided results from genome-wide association analysis of single nucleotide 
polymorphisms (SNPs) with fasting insulin adjusting for age, sex, BMI, and principal 
components of genetic information to account for potential population stratification 
(Price et al. 2006). Fasting insulin level was measured from whole blood, plasma, or 
serum, and was log-transformed for analysis. Both genotyped and imputed SNPs were 
used. We include genotyped SNPs that passed quality control inclusion criteria, (i) 
Hardy-Weinberg equilibrium P-value of >1e-6; (ii) minor allele frequency of > 1%; (iii) 
variant call rate > 95%. Imputation was performed based on the International HapMap 
Project (HapMap) Phase 2 Utah residents of Northern and Western European ancestry 
(CEU) population using MACH (Y. Li et al. 2009; Y. Li et al. 2010) (r2 >0.3) or 
IMPUTE (Howie, Donnelly, and Marchini 2009; Marchini et al. 2007) (proper_info>0.4) 
 
It has been shown that BMI influences  the heritability of insulin resistance (X Wang et 
al. 2009) and modifies the association of genotypes with insulin resistance (Mayer et al. 
1996; Herbert et al. 2006). Thus, there is interest in finding genetic variants associated 
with fasting insulin accounting for heterogeneity attributed to BMI. Three study 
characteristics, mean age, mean BMI and the proportion of the sample of each gender, 
were reported in supplementary material of the original paper (Manning et al. 2012).  For 
ease of comparison with our simulation study, we selected the two covariates showing the 
most variability across studies, mean BMI and mean age, to include as random effects to 
accommodate additional heterogeneity that may not have been accounted for in the 
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original GWAS. Because our approach showed competitive power in the simulation 
study, we evaluated our approach and compared it to the conventional FE model. 
  
As described in the simulation study, we used an empirical distribution to calculate p-
values instead of the asymptotic distribution due to its conservativeness. We randomly 
selected 100,000 SNPs that were present across all of the fifteen cohorts and constructed 
the empirical distribution using the corresponding standard errors of the effects of 
randomly selected SNPs as follows. First, we simulated null effect sizes from 𝑀𝑁(𝟎, 𝑹) 
where the diagonal elements of the covariance matrix 𝑅 were the variances of the SNP 
from the fifteen studies while the off-diagonal elements were zero. Second, we 
numerically estimated 𝛽 and 𝜏2’s and computed the null LRT statistics. Third, we 
estimated the scaled-shifted parameters (a, b, and c) of the corrected null 
distribution, 𝑎 𝜒1
2 + 𝑏 𝜒2
2 + 𝑐, that we selected based on its anti-conservativeness and 
controlled type I error rates by comparing 100,000 random 𝜒1
2 and 𝜒2
2 values to the 
computed null LRT statistics. With the estimated scaled-shifted parameters, we 
constructed an empirical distribution, 0.749 𝜒1
2 + 0.318 𝜒2
2 − 0.08, with which we 
evaluated test statistics and computed p-values.  
 
3.4.3 Meta-analysis Results 
The Quantile-Quantile (Q-Q) plot with p-values computed from the empirical distribution 
against expected quantiles from 0 and 1, and the genome-wide association plot using the 
meta-analysis results from the fifteen studies in the MAGIC consortium are shown in 
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Figures 3.4 and 3.5. Table 3.3 lists all of variants identified in the meta-analysis with p-
value < 1 × 10−6 using either our proposed LRT approach or the conventional FE 
approach. We restricted the meta-analysis results to variants present in at least five 
participating studies and with sample size greater than one-third of the total possible 
sample size. We found thirteen SNPs that had p-value < 1 × 10−6 for either our LRT or 
the FE approach.  Among the thirteen variants, we found three SNPs located within 
genes, NMT2 and COBLL1, and one SNP 69kb downstream of TSHZ3 and the other 
SNPs in intergenic regions with IRS1 or PDGFC as the closest gene.  
 
COBLL1, Cordon-Bleu WH2 Repeat Protein-Like 1, is a protein coding gene and is 
known to be associated with Type 2 diabetes in European-descent population 
(Albrechtsen et al. 2013), and fasting insulin and HOMA-IR levels in overweight and 
obese children (Mancina et al. 2013). Two SNPs, rs10490694 and rs6738627, in COBLL1 
were identified that were different from the reported SNP in the Manning et al. study 
(Manning et al. 2012) with LD R2=1 and 0.282, respectively. NMT2 (N-
myristoyltransferase) is a novel locus that has not been previously found and is the only 
SNP that reaches genome-wide significance (rs11592551, p-value=1.28 × 10−8). NMT2 
is a protein coding gene and Gene Ontology (GO) annotation related to this gene may 
include glycylpeptide N-tetradecanoyltransferase activity (Thinon et al. 2014). 
 
In order to explore the performance of our approach compared to FE under relatively 
heterogeneous situations, we compared p-vales of our approach and corresponding p-
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values of FE for heterogeneous SNPs, defined by Q-statistic heterogeneity p-value < 0.05 
or I2 > 50%. Although it is known to be low power, a significant Q-statistic (p-value < 
0.05) may imply the presence of heterogeneity. I2 measures the extent of heterogeneity 
and its value > 50% may indicate substantial heterogeneity (Higgins and Thompson 
2002). Figure 3.6 suggests that our approach generally gives lower p-values than FE 
model when substantial heterogeneity is present.  
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Table 3.3 Variants associated with Fasting Insulin adjusting for mean age and mean BMI at p-value less than 1 × 10−6 of 
either our new LRT or FE models 
Chromosome rs number 
Position 
(build 36) 
# Sample size 
New LRT  
P-value a 
FE  
P-value a 
I2 b 
Heterogeneity  
P-value b 
Gene c 
10 rs11592551 15243953 31694 1.3E-08 4.3E-09 51.33 0.02 NMT2* 
2 rs10490694 165256815 28629 3.7E-07 1.3E-07 27.38 0.18 COBLL1* 
19 rs1874492 36388218 35616 4.0E-07 3.4E-07 31.07 0.12 TSHZ3§ 
2 rs6738627 165252696 28629 4.5E-07 1.6E-07 19.55 0.26 COBLL1* 
2 rs2972146 226808942 35616 6.2E-07 4.6E-06 54.13 6.5E-03 IRS1 
2 rs2943645 226807424 35616 6.4E-07 4.6E-06 53.87 6.8E-03 IRS1 
2 rs2943652 226816690 35616 6.9E-07 3.7E-06 53.01 8.2E-03 IRS1 
2 rs2943650 226814165 35616 7.0E-07 3.2E-06 53.14 7.9E-03 IRS1 
2 rs2972144 226809655 35615 7.1E-07 4.0E-06 54.43 6.1E-03 IRS1 
2 rs2943646 226807778 35579 8.0E-07 5.3E-06 53.64 7.2E-03 IRS1 
2 rs2138157 226811961 35616 8.2E-07 6.0E-06 51.24 0.01 IRS1 
14 rs1642875 76114390 35616 1.1E-06 3.9E-07 0.00 0.85 ESRRB§ 
4 rs13141804 157582999 35616 2.1E-06 7.7E-07 0.00 0.61 PDGFC 
 a New LRT, our new LRT method; FE, Fixed effects. 
 b I2, the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error; Heterogeneity  
P-value, Q (Chi-square)-statistic p-value.  
c Variants are located *within gene, §within 100kb of gene, and the rest of them are around 500kb in distance. 
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Figure 3.4 Quantile-Quantile (Q-Q) plot with p-values from the empirical distribution 
 
 
 
Figure 3.5 Genome-wide association plot from the fifteen MAGIC GWAS results using 
our new LRT method 
 
The red dotted lines indicate 𝛼 = 10−6 and 5 × 10−8 significance levels 
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Figure 3.6 Comparison of our new LRT and FE models where substantial heterogeneity 
is present 
 
(A) Heterogeneity, Q-statistic p-value is less than 0.05 which indicates heterogeneity in 
effect size among studies is present; (B) when I2, the percentage of the variability in 
effect estimates that is due to heterogeneity rather than sampling error, is greater than 
50%. 
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3.5 Discussion 
We proposed a new statistical approach to accommodate multiple random effects 
introduced by study-level characteristics in the context of meta-analysis of potentially 
heterogeneous studies. As shown in  previous simulation studies (B. Han and Eskin 2011; 
Hong et al.), the conventional RE model was less powerful than the FE model even when 
heterogeneity was present. Further, our proposed model improved power by assuming no 
association and no heterogeneity under the null hypothesis. Under the assumption that the 
sources of heterogeneity were related to study characteristics, our approach jointly tested 
the main effects and study-level characteristics that may influence the main effects. Our 
simulation study showed that our approach had greater power than the conventional FE 
and RE models and can be useful in identifying underlying effects associated with an 
outcome when heterogeneity in effects among studies in the meta-analysis exists and is 
considered in the analysis. 
 
In the application to the genome-wide association analysis of fasting insulin from the 
fifteen studies from MAGIC consortium, our approach yielded eleven SNPs that had p-
values < 10e-6, while FE found six SNPs. Two SNPs were found only using the FE 
model; these two SNPs showed no heterogeneity (I2=0) among studies.  When there is no 
heterogeneity, the FE model tends to perform better than any other random-effects model 
(Hong et al.).  
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As previously mentioned, the examination of the effect of study-level characteristics is of 
high interest to investigators in many fields including clinical trials and statistical 
genetics (Simmonds and Higgins 2007; Sterne et al. 2002; Greenland 1987; Manning et 
al. 2012). Among several approaches to explore interaction effects of the study 
characteristics, our approach jointly tests the main effect and the study-level covariate 
effects that may influence the main effect.   This may, in practice, be similar to a joint 
meta-analysis of the main and interaction effects. However, one should remember that 
our approach considers only study-level characteristics rather than individual-level 
characteristics, and thus there is a  possibility of aggregation bias (Greenland 1987). 
Aggregation (or ecological) bias arises when the relation between effect size and study-
level characteristics is not the same as that between individual values of outcome and 
covariates. For example, the accountability of the variability of BMI among studies in a 
meta-analysis may not be the same as that of the variability of all of individuals in all of 
the studies. The study-level covariates are likely to misrepresent the individual measures. 
However, our approach is still useful especially when only summary measures are 
available. The joint meta-analysis (jointly testing main effects and interaction effects) or 
the meta-analysis of only interaction effects require the interaction effect estimates from 
each of the included studies. For meta-analysis of results extracted from literature or 
collected from studies conducted by different researchers, it may either be infeasible or 
take considerable time and effort to collect such data and the unavailability of the data 
restricts the study design to perform such meta-analyses. One advantage of our approach 
is that it does not require the access to individual data and can use summary data 
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extracted from literature or a GWAS result repository as long as study-level measures of 
variables are available.  
 
Although our approach is proposed in the general context of meta-analysis, it can be 
applied to a meta-analysis of ethnically diverse studies such as trans-ethnic meta-analysis 
of GWAS. Meta-analysis is commonly used in genetic studies and has been a highly 
successful tool for identifying common genetic variants associated with diseases and 
disease-associated quantitative traits. Because the FE model provides a pooled effect size 
and p-value, it has predominantly been used among European-descent studies. As the 
number of GWAS increases both within the European ancestry and across other ethnic 
ancestries, trans-ethnic meta-analysis, meta-analyzing over multiple GWAS across 
genetically diverse populations, suggests both opportunities and challenges. Because 
genetic architecture is distinctive in different ancestral populations, it is ambiguous how 
to better leverage different linkage disequilibrium, different spectra of causal variants and 
their allele frequencies. However, properly analyzing the evidence from diverse 
populations accounting for heterogeneity would improve power (Y. Li and Keating 2014; 
Morris 2011; Hong et al.) and would also provide valuable opportunities to explore 
genetic variants that are either transferable across populations or unique to a certain 
ethnicity (Liu et al. 2013; Liu et al. 2012) and enhance the ability to fine-map causal 
signals (Boerwinkle and Heckbert 2014; Liu et al. 2012; Franceschini et al. 2012). 
Because of this genetic heterogeneity in a trans-ethnic meta-analysis, the FE model may 
violate its homogeneity assumption and so should be avoided in application (Cantor, 
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Lange, and Sinsheimer 2010; de Bakker et al. 2008; Zeggini and Ioannidis 2009). In 
contrast, our approach takes potential heterogeneity into account in the form of study 
covariates and thus can be used in trans-ethnic meta-analysis of GWAS. 
 
In summary, we proposed a statistical framework for the meta-analysis of potentially 
heterogeneous studies. Our approach accommodates multiple sources of heterogeneity 
related to study characteristics and generally achieves higher power than the FE model 
approach when heterogeneity in effect size across studies is substantial. Although it is 
somewhat limited in examining the cause of heterogeneity and challenging in 
interpretation because we only consider study-level measures rather than individual-level 
measures, our method can extend the ability of currently used FE and RE meta-analytic 
methods. We have also demonstrated that our method is computationally feasible to 
apply to data much larger than conventional clinical datasets such as genetics data. 
Because our approach allows for heterogeneity attributed to study characteristics, the 
application of our method can be extended beyond the typical synthesis of summary 
information of published data from literature and has the ability to meta-analyze over 
studies with big data such as genome-wide association studies with outcomes measured 
using different techniques, diverse populations, or multiple diseases with similar etiology.  
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Chapter 4 Score Test Approach to Statistical Model with Multiple Random 
Effects to Account for Heterogeneity in the Meta-Analysis 
 
4.1 Introduction 
Genome-wide association studies (GWAS) have achieved great success, however, the 
effect size of genetic variants is usually relatively modest and many studies with small to 
moderate sample size have lacked power to identify genetic determinants that are weakly 
associated with complex disease. The variants with weaker associations can be identified 
by increasing the sample size, and thus, power (McCarthy et al. 2008; Manolio et al. 
2009). Meta-analysis is a practical approach to explore those weaker signals. The meta-
analysis approach effectively improves power by increasing total sample size and is as 
efficient as combining individual participant data under most conditions (Lin and Zeng 
2010). Hence, investigators provide summary statistics of the individual studies and 
meta-analyze them to detect those weaker signals with better power.  
 
Although the meta-analysis approach is popular in genetics studies, it has been mostly 
restricted to studies of samples of European-ancestry. Because the genetic architecture is 
likely to be similar across samples having the same ancestral population, studies have 
commonly used inverse-variance-weighted fixed-effect (FE) meta-analysis. This model 
makes the assumption that there is no heterogeneity of effect size across contributing 
studies. However, as the number of GWAS in populations with a wide range of ancestries 
increases, investigators are interested in combining the summary statistics from as many 
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available studies as possible regardless of their ancestry.  One advantage of combining 
studies with different genetic backgrounds is an increase in total sample size and hence a 
boost in power for novel discovery of associations between genetic variants and complex 
traits (Y. Li and Keating 2014). Combining studies with diverse ancestries also enhances 
fine-mapping of functional genetic variants by leveraging LD over different genetic 
structures (Liu et al. 2012; Liu et al. 2014; Boerwinkle and Heckbert 2014; Franceschini 
et al. 2012; Y. Li and Keating 2014).  
 
When studies with diverse ancestries are meta-analyzed, the genetic architecture of the 
studies may not be homogeneous and the use of the FE meta-analysis is inappropriate. 
The random effect (RE) model accounts for the heterogeneity in the effect sizes, correctly 
estimates the between-study variance, and provides more appropriate confidence intervals 
for the pooled effect size estimate (Fleiss 1993; Hedges and Olkin 1985). However, the 
standard RE model has low power due to its conservative null hypothesis (Hedges and 
Olkin 1985; B. Han and Eskin 2011; Hong et al.) and its assumption of a single source of 
heterogeneity. Because variation across studies may arise due to multiple sources from 
complex study designs, populations, or different environmental exposures, assuming a 
single source of heterogeneity may not be realistic.  
 
In chapter 3 we developed a new likelihood ratio test (LRT) that can accommodate 
multiple sources of heterogeneity using a linear mixed effects model. The LRT is formed 
by maximizing the likelihood function over both the restricted and unrestricted parameter 
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spaces (Casella and Berger 2002). If we consider many possible restrictions in the 
parameter space, the evaluation of the maximum likelihood may be inefficient and 
possibly intractable. These issues can be avoided by using a score test. The main 
advantage of the score test is that it requires the estimation of model parameters only 
under the null hypothesis, and it is computationally more efficient and asymptotically 
equivalent to the likelihood ratio test. 
 
In this chapter, we propose a score test in the context of a meta-analysis evaluating the 
beta coefficients for genetic variants and the between-study variances pertinent to study 
covariates. This method provides a joint test of significance and a test of heterogeneity. 
We present a simulation study to compare this approach to the LRT developed in chapter 
3.  
 
 
4.2 Methods  
4.2.1 Linear Mixed Effects Model with Multiple Random Effects 
4.2.1.1 Notations and Assumptions 
We consider the linear mixed-effect model and derive a score test statistic that accounts 
for heterogeneity. We assume that association results are gathered from N independent 
studies where genetic variants are either genotyped or imputed, and a trait of interest is 
also measured. Summary statistics assessing association between the trait and genetic 
variants, including the effect estimate (𝑏𝑖) and its standard error (𝑠𝑒(𝑏𝑖)), are available 
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from these studies as well as study-level variables (𝑧𝑖𝑗 , 𝑖 = 1,… ,𝑁 𝑎𝑛𝑑 𝑗 = 1,… , 𝑟;  𝑁 is 
the number of studies and 𝑟 is the number of variables). We assume that the effect size 
across the studies may vary according to the study-level variables and heterogeneity in 
effect size may be introduced by these variables. We incorporate the heterogeneity by 
treating the variables as random effects using a linear mixed effects model. The model is  
𝒃 = 𝜷 + 𝒁𝒗 + 𝒆 . 
The notations and model assumptions are the same as described in chapter 3. Note that 
𝒃 and 𝜷 are vectors of observed effect estimates and a mean vector of the unknown true 
effect parameters, respectively. The Z is a matrix of study-level variable measures that 
are related to the random effects, 𝒗. 
𝒃 = [
𝑏1
⋮
𝑏𝑁
] , 𝜷 = 𝛽 [
1
⋮
1
] , and      𝒁 = [
𝑧11 … 𝑧1𝑟
⋮ ⋱ ⋮
𝑧𝑁1 … 𝑧𝑁𝑟
] . 
Generally, the random effects, 𝒗, and the residual errors, 𝒆, are assumed to be 
uncorrelated and to follow multivariate normal distributions with mean 0 and covariance 
matrices, 𝜮𝑣 and 𝑹, respectively,  
𝒗 ~ 𝑵(𝟎, 𝜮𝑣) , 
𝒆 ~ 𝑵(𝟎,𝑹) , 
where 
𝜮𝑣 = 𝑣𝑎𝑟[𝒗] = [
𝜏1
2 ⋯ 𝜏1𝑟
⋮ ⋱ ⋮
𝜏𝑟1 ⋯ 𝜏𝑟
2
]  𝑎𝑛𝑑 𝑹 = [
𝜎1
2 ⋯ 0
⋮ ⋱ ⋮
0 ⋯ 𝜎𝑁
2
] . 
Because we assume that the random effects, elements of 𝒗, are uncorrelated, the off-
diagonal elements of the covariance matrix, 𝜮𝑣, are zero (𝜏𝑚𝑛 = 𝜏𝑛𝑚 = 0, for all 𝑚 ≠
92 
 
 
𝑛). Also we assume that the estimated standard errors, 𝑠𝑒(𝑏𝑖), of the effect estimates are 
true parameter values (Higgins and Thompson 2002) and so replace the within-study 
variances, 𝜎𝑖
2 of the covariance matrix of the residual errors, 𝒆. Under these assumptions, 
the notations can be simplified as  
𝜮𝑣 = 𝑣𝑎𝑟[𝒗] = [
𝜏1
2 ⋯ 0
⋮ ⋱ ⋮
0 ⋯ 𝜏𝑟
2
]  𝑎𝑛𝑑 ?̂? = [
𝑠𝑒(𝑏1)
2 ⋯ 0
⋮ ⋱ ⋮
0 ⋯ 𝑠𝑒(𝑏𝐾)
2
] , 
and the marginal distribution of 𝒃 follows a multivariate normal distribution with mean 𝜷 
and covariance matrix 𝑾, 
𝒃~𝑀𝑁(𝜷,𝑾), 
where 𝑾 = 𝒁𝜮𝒗𝒁
′ + 𝑹. We then can obtain a likelihood function under the marginal 
distribution of 𝒃 as follows, 
𝐿(𝒃, 𝒁, 𝑹|𝜷, 𝜮𝒗) =
1
(√2𝜋)𝑘
|𝑾|−
1
2 ∗ 𝑒𝑥𝑝 (−
1
2
(𝒃 − 𝜷)′𝑾−1(𝒃 − 𝜷)). 
We use this likelihood function to derive score functions, the information matrix and then 
the score test statistic. 
 
4.2.1.2 Score Test Statistic 
The usual form of the score function 𝑼(𝜽) is the derivative of the log-likelihood with 
respect to the parameters of interest, that is, 𝛽, 𝜏1
2, … , 𝜏𝑟
2. In addition, the Fisher 
information 𝑰(𝜽) provides an estimate of the covariance matrix of the score 
function 𝑼(𝜽). The log-likelihood function is 
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𝑙(𝒃, 𝒁, 𝑹|𝜷, 𝜮𝒗) = 𝐶 −
1
2
𝑙𝑛|𝑾| −
1
2
(𝒃 − 𝜷)′𝑾−1(𝒃 − 𝜷), 
where 𝐶 = −
1
𝑘
𝑙𝑛(√2𝜋). 
The score function can be obtained from the log-likelihood function by the first 
derivative of the log-likelihood function with respect to the parameters of interest 
𝑼(𝜽) =
𝜕𝑙
𝜕𝜽
, 
where 𝜽 = (𝛽, 𝜏1
2, … , 𝜏𝑟
2). The score function has mean 𝑬[𝑼(𝜽)] = 𝟎 and 
variance 𝑉𝑎𝑟[𝑼(𝜽)] = 𝑰(𝜽). The information matrix can also be obtained by the negative 
expectation of the second derivatives of the log-likelihood function with respect to the 
parameters of interest, (𝛽, 𝜏1
2, … , 𝜏𝑟
2), as follows 
𝐼(𝜃𝑝𝑞) = −𝐸 [
𝜕2𝑙
𝜕𝜃𝑝𝜕𝜃𝑞
], 
where 𝜃𝑝 ∈ 𝜽 and 𝜃𝑞 ∈ 𝜽. We can obtain the first and second derivative of log-likelihood 
function as follows. We present detailed derivations in Appendix D. 𝑱1 is a N-
dimensional vector of 1’s. 
 
𝜕2𝑙
𝜕𝛽2
= −𝑱1
′ 𝑾−1𝑱1, 
𝜕2𝑙
𝜕𝛽𝜕𝜏𝑖
2 =
𝜕2𝑙
𝜕𝜏𝑖
2𝜕𝛽
= −(𝒃 − 𝜷)′(𝑾−1𝒛𝑖𝒛𝑖
′𝑾−1)𝑱1, 𝑖 = 1,… , 𝑟,  
𝜕2𝑙
𝜕𝜏𝑖
2𝜕𝜏𝑗
2 = 
1
2
𝑡𝑟(𝑾−1𝒛𝑗𝒛𝑗
′𝑾−1𝒛𝑖𝒛𝑖
′) 
−
1
2
(𝒃 − 𝜷)′(𝑾−1𝒛𝑗𝒛𝑗
′𝑾−1𝒛𝑖𝒛𝑖
′𝑾−1 +  𝑾−1𝒛𝑖𝒛𝑖
′𝑾−1𝒛𝑗𝒛𝑗
′𝑾−1)(𝒃 − 𝜷),  
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𝑖 = 1, … , 𝑟 and 𝑗 = 1,… , 𝑟. 
 
Hence the vector of score functions and the information matrix for our parameters are 
𝑼(𝜽) = [
𝑈(𝛽)
𝑈(𝜏1
2)
⋮
𝑈(𝜏𝑟
2)
] , 
where  
    𝑈(𝛽) = (𝒃 − 𝜷)′𝑾−1𝑱1, 
    𝑈(𝜏𝑖
2) = −
1
2
𝑡𝑟(𝑾−1𝒛𝑖𝒛𝑖
′) +
1
2
(𝒃 − 𝜷)′(𝑾−1𝒛𝑖𝒛𝑖
′𝑾−1)(𝒃 − 𝜷), 𝑖 = 1, … , r, 
and  
𝑰(𝜽) = −𝐸
[
 
 
 
 
 
 
 
 
 
 
𝜕2𝑙
𝜕𝛽2
𝜕2𝑙
𝜕𝛽𝜕𝜏1
2
𝜕2𝑙
𝜕𝜏1
2𝜕𝛽
𝜕2𝑙
𝜕𝜏1
2𝜕𝜏1
2
⋯
𝜕2𝑙
𝜕𝛽𝜕𝜏𝑟2
𝜕2𝑙
𝜕𝜏1
2𝜕𝜏𝑟2
𝜕2𝑙
𝜕𝜏2
2𝜕𝛽
𝜕2𝑙
𝜕𝜏2
2𝜕𝜏1
2
⋮ ⋮
⋱ ⋮
𝜕2𝑙
𝜕𝜏𝑟2𝜕𝛽
𝜕2𝑙
𝜕𝜏𝑟2𝜕𝜏1
2 ⋯
𝜕2𝑙
𝜕𝜏𝑟2𝜕𝜏𝑟2]
 
 
 
 
 
 
 
 
 
 
 , 
 
We are interested in testing the null hypothesis H0: 𝛽 = 0, 𝜏1
2 = 0,… , and 𝜏𝑟
2 = 0, versus 
the alternative hypothesis H1: 𝛽 ≠ 0, 𝜏1
2 > 0,… , or 𝜏𝑟
2 > 0. We construct a score test 
statistic using the derived score vector and the information matrix. The main advantages 
of the score test are that it requires the estimation of the parameters only under the null 
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hypothesis and it is asymptotically equivalent to the likelihood ratio test. Under the null 
hypothesis, we can simplify our score function and information matrix as follows 
𝑼(𝜽0) = [
𝑈(𝛽0)
𝑈(𝜏10
2 )
⋮
𝑈(𝜏𝑟0
2 )
] , 
where 
    𝑈(𝛽0) = 𝒃
′𝑹−1𝑱1, 
    𝑈(𝜏𝑖0
2 ) = −
1
2
𝑡𝑟(𝑹−1𝒛𝑖𝒛𝑖
′) +
1
2
𝒃′(𝑹−1𝒛𝑖𝒛𝑖
′𝑹−1)𝒃, 𝑖 = 1,… , r, 
 
and  
𝑰(𝜽0) =
[
 
 
 
 
 
 
 
 
 
 
 −𝐸 [
𝜕2𝑙
𝜕𝛽2
]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝛽𝜕𝜏1
2]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝜏1
2𝜕𝛽
]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝜏1
2𝜕𝜏1
2]
𝜽0
⋯
−𝐸 [
𝜕2𝑙
𝜕𝛽𝜕𝜏𝑟2
]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝜏1
2𝜕𝜏𝑟2
]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝜏2
2𝜕𝛽
]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝜏2
2𝜕𝜏1
2]
𝜽0
⋮ ⋮
⋱ ⋮
−𝐸 [
𝜕2𝑙
𝜕𝜏𝑟2𝜕𝛽
]
𝜽0
−𝐸 [
𝜕2𝑙
𝜕𝜏𝑟2𝜕𝜏1
2]
𝜽0
⋯ −𝐸 [
𝜕2𝑙
𝜕𝜏𝑟2𝜕𝜏𝑟2
]
𝜽0]
 
 
 
 
 
 
 
 
 
 
 
 , 
where 
    −𝐸 [
𝜕2𝑙
𝜕𝛽2
]
𝜃0
= 𝑱1
′ 𝑹−1𝑱1, 
    −𝐸 [
𝜕2𝑙
𝜕𝛽𝜕𝜏𝑖
2]
𝜃0
= −𝐸 [
𝜕2𝑙
𝜕𝜏𝑖
2𝜕𝛽
]
𝜃0
= 0, 𝑖 = 1,… , 𝑟,  
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    −𝐸 [
𝜕2𝑙
𝜕𝜏𝑖
2𝜕𝜏𝑗
2]
𝜃0
= 
1
2
𝑡𝑟(𝑹−1𝒛𝑗𝒛𝑗
′𝑹−1𝒛𝑖𝒛𝑖
′),          𝑖 = 1,… , 𝑟 and 𝑗 = 1,… , 𝑟. 
 
The vector 𝒃 contains the observed effect estimates, the vectors 𝒛𝑖 and 𝒛𝑗 have study-
level measures, and the within-study covariance matrix 𝑹 has the squared standard errors 
of the effect estimates for the diagonal elements and zero for the off-diagonal values. All 
these values are assumed to be known as described in 4.2.1.1. The score test statistic is 
thus 
 
𝑇𝑠 = 𝑼
′(𝜽𝟎)𝑰(𝜽𝟎)
−1𝑼(𝜽𝟎), 
 
and the score vector 𝑼(𝜽𝟎) and the information matrix 𝑰(𝜽𝟎) are defined in the previous 
paragraph. 
 
4.2.2 Asymptotic Distribution 
The statistical significance of the score test 𝑇𝑠 could be assessed using its asymptotic 
distribution. For testing the null hypothesis, H0: 𝛽 = 0, 𝜏1
2 = 0,… , and 𝜏𝑟
2 = 0, the 
parameter 𝛽 is unbounded and the asymptotic distribution of a score test for 𝛽 is a 𝜒1
2 
distribution. The parameter 𝜏2 is bounded to be non-negative in the parameter space; 
however, 𝜏 is unbounded and thus the asymptotic distribution of a score test for 𝜏 is a 𝜒1
2 
distribution (Boos 1992). If the score test 𝑇𝑠 is constructed with respect to all parameters 
that are unbounded, its asymptotic distribution follows a 𝜒𝑔
2 distribution with 𝑔 degrees 
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of freedom determined by the number of parameters specified under the null hypothesis 
(Boos 1992). We derive the score functions and information matrix with respect to both 
𝜏2 and 𝜏 in Appendix E and show that the test statistics derived by both parameters are 
the same (Dupuis, Siegmund, and Yakir 2007b; Kumar 1973; Misra 1972). This result 
implies that our score test 𝑇𝑠 can also test H0: 𝛽 = 0, 𝜏1 = 0,… , and 𝜏𝑟 = 0, and 
therefore, we may reasonably assume that our score test statistic 𝑇𝑠 asymptotically 
follows a 𝜒𝑔
2 distribution with 𝑔 = 1 + 𝑟 degrees of freedom.  
 
4.3 Simulation Study  
4.3.1 Study Design of Simulation 
In the simulation study, we evaluated the type I error rates and power of the proposed 
score test statistic. We considered the case of two random effects throughout the 
simulation study. The two random effects were represented by two study-level covariates. 
We considered four different combinations of the covariates in a model; two continuous, 
two dichotomous, two proportional variables, and a combination of a continuous and a 
dichotomous variables. We varied the number of studies to evaluate the type I error rates 
and additionally varied the effect size and the size of between-study variances to evaluate 
power. We compared the performance of the score test to the LRT approach from chapter 
3.  
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4.3.1.1 Type I error Simulation 
We evaluated the type I error rates under the null hypothesis by setting all of the 
parameters of interest to zero, that is, H0:  𝛽 = 0,  𝜏1
2 = 0, 𝜏2
2 = 0. The overall steps of 
data simulation were similar to those in chapter 3. We first simulated the error variance 
𝜎𝑖
2 from a 𝜒1
2 distribution and generated observed effect sizes from 𝑏𝑖~𝑁(0, 𝜎𝑖
2) for the 
ith study. We excluded extreme values of 𝜎𝑖
2 that were less than 20th percentile or greater 
than 80th percentile in order to mimic the practical range of variances in genetic studies 
such that the sample size ratio of small sample sized study (300) to relatively large 
sample sized study (10,000) is around 30. The study-level covariates 𝑧𝑖𝑗 were generated 
according to the variable types. The continuous variables were generated 
from 𝑁 (0.5,
1
12
). Here, we made the distribution for continuous covariates similar to that 
of the proportion covariates, Uniform(0,1), with mean 0.5 and variance 
1
12
. The 
dichotomous variables were generated from Bernoulli(1, 𝑝 = 0.5). The proportion 
variables were generated from Uniform(0, 1). We varied the number of studies 𝑁 from 
10, 20, 50 and 100 to evaluate the type I error rates. We computed the score test statistics 
𝑇𝑠 and evaluated p-values from the asymptotic distribution (Table 4.1). However, we 
observed highly inflated type I error rates. Our attempts to obtain controlled type I error 
rates are described in Appendix F. We decided ultimately to use an empirical 
distribution. 
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Table 4.1 Type I error rates evaluated from a 𝝌𝟑
𝟐 distribution 
 Continuous Continuous+Dichotomous Dichotomous Proportional 
α=0.05 0.073 0.079 0.078 0.079 
α=0.01 0.042 0.047 0.050 0.052 
 
4.3.1.2 Empirical distribution  
We constructed an empirical distribution from additional null simulations. We generated 
a hundred null effect sizes from each replicate, 𝑏𝑒𝑚𝑝~𝑁(0, 𝜎𝑖
2). So we obtained a 
hundred null score statistics  𝑇𝑒𝑚𝑝 for each simulation replicate (or SNP) and aggregated 
the computed null score statistics to construct the empirical null distribution. The p-value 
is computed as the proportion of empirical score values that are greater or equal to the 
observed score test.  
 
4.3.1.3 Power Simulation 
We simulated data for power in a similar manner to the type I error simulation. We 
generated the error variance 𝜎𝑖
2 from a 𝜒1
2 distribution for the elements of the error 
covariance matrix 𝑹, and pre-specified true effect sizes 𝛽𝑖, 𝑖 = 1,… ,𝑁, between-study 
variances 𝜏𝑗
2, 𝑗 = 1, 2 for each 𝑁. We generated the design matrix 𝒁 for the study-level 
covariates where each element 𝑧𝑖𝑗  of the design matrix 𝒁 was generated according to the 
variable types described in the type I error simulation. Using these values, we generated 
the observed effect sizes from a multivariate normal distribution 𝒃~𝑀𝑁(𝜷,𝑾) where 𝜷 
was a vector of the pre-specified true effect sizes and 𝑾 was calculated from 𝑾 =
100 
 
 
𝒁𝜮𝒗𝒁
′ + 𝑹, and 𝜮𝒗 = [
𝜏1
2 0
0 𝜏2
2]. We computed the score test statistic 𝑇𝑠 and 
simultaneously computed the null score statistics 𝑇𝑒𝑚𝑝 to construct the empirical null 
distribution as described in the previous section. We calculated the p-value from the 
corresponding empirical null distribution.  
 
We evaluated power in three heterogeneity scenarios testing 𝐻0: 𝛽 = 0, 𝜏1
2 = 0, 𝜏2
2 = 0  
versus 𝐻1: 𝛽 ≠ 0, 𝜏1
2 ≠ 0, or 𝜏2
2 ≠ 0. In scenario 1 (Effect-size Homogeneity scenario), 
there is no heterogeneity between studies: the true between-study variances 𝜏1
2 and 𝜏2
2 are 
zero while 𝛽 is non-zero. In this scenario, we generated the observed effect sizes 
from 𝒃~𝑀𝑁(𝜷,𝑹). In scenario 2 (Two Random Effects scenario), the between-study 
variances 𝜏1
2 and 𝜏2
2 are non-zero. Hence we generated the observed effect sizes 
from 𝒃~𝑀𝑁(𝜷,𝑾). In scenario 3 (One Random Effects scenario), the between-study 
variance 𝜏1
2 was non-zero while 𝜏2
2 was zero. In this scenario, we generated the observed 
effect sizes from 𝒃~𝑀𝑁(𝜷,𝑾), where 𝑾= 𝒁𝜮𝑣𝒁
′ + 𝑹, and 𝜮𝑣 = [
𝜏1
2 0
0 0
]. Under each 
scenario, we generated study-level covariates as described in 4.3.1.1. We additionally 
varied the effect sizes 𝛽 from 0.01 to 0.05, 0.1, 0.15 and 0.2, the size of between-study 
variance  𝜏1
2 from 0.05 to 0.1, 0.2, 0.5, 1 and 2, and the number of studies 𝑁 as 10, 
20, 50 and 100. 
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4.3.2 Simulation Results 
4.3.2.1 Type I error Simulation 
Figure 4.1 shows the type I error rates of the score test at 𝛼 = 0.001 and 95% confidence 
intervals for the four different combinations of the study covariates varying the number 
of studies. The type I error rates were calculated by the proportion of simulations that 
passed the p-value less than or equal to the 𝛼 level. For all scenarios, the 95% confidence 
intervals covered the 𝛼 level.  
 
Figure 4.1 Empirical type I error rates and its 95% confidence intervals for the four 
different combinations of the study covariates at 𝛼 = 0.001 
 
CC, two continuous variables; CD, a combination of continuous and dichotomous 
variables; DD, two dichotomous variables; PP, two proportions 
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4.3.2.2 Power Simulation 
We evaluated power of the score test and compared it to that of the LRT approach in 
which p-values were calculated using both asymptotic (LRT only) and corrected null 
distributions from chapter 3. Figure 4.2 shows the Effect-size Homogeneity scenario 
(Scenario 1) results. In this scenario, power of the score test improved when the number 
of studies or the effect size increased. When the covariates were proportions or 
continuous variables power of the score test was similar to the LRT approach using the 
correct null distribution. When the covariates were dichotomous or the combination of 
the continuous and dichotomous variables, power of the score test was a little bit below 
the LRT with corrected distribution. When the covariates were dichotomous variables, 
the power of the score test was greater than that of LRT with the asymptotic distribution 
and less than that of LRT with the corrected distribution when 𝑁 = 50 or 𝛽 = 0.1 but the 
power of the score test became similar to that of LRT with the asymptotic distribution 
when 𝑁 = 100 or 𝛽 = 0.2. 
 
Figure 4.3 shows the power results under the Two Random Effects scenario (Scenario 2) 
where we introduce heterogeneity in effect size across studies through the study 
covariates. When the covariates were proportions, the score test showed similar power to 
the LRT approach using the correct null distribution. When the covariates were 
dichotomous the power gain with increasing parameter values (𝑁, 𝛽, or 𝜏1
2 and 𝜏2
2) was 
lower for the score test than LRT approach. When the covariates involved continuous 
variables, either two continuous variables or the combination of continuous and 
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dichotomous variables, the score test was less powerful than either LRT approach. The 
One Random Effects scenario (Scenario 3) showed similar results as in scenario 2. The 
results of scenario 3 are shown in Figure 4.4.  
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Figure 4.2 Power of the score test and LRT tests under the Effect-size Homogeneity 
scenario (Scenario 1) 
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Figure 4.3 Power of score test and LRT tests under the Two Random Effects scenario 
(Scenario 2) 
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Figure 4.4 Power of score test and LRT tests under the One Random Effects scenario 
(Scenario 3) 
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4.4 Discussion 
In this chapter, we proposed a score test approach for meta-analysis of heterogeneous 
studies when the heterogeneity in effect size is explained by study-level characteristics. 
Because we assume no main effect and no heterogeneity under the null hypothesis, the 
proposed test statistic jointly tests the main effect and the heterogeneity pertinent to study 
covariates. The proposed approach only requires summary statistics of SNPs and study-
level covariate measures from each study. We have explored different types of study 
covariates on the performance of the score test in the simulation study.  
 
Compared with the LRT approach using the corrected null distribution, the score test 
approach has lower power under most of the scenarios. The power of the score test is 
similar to the LRT when both covariates are continuous or proportions under the Effect-
size Homogeneity scenario (Scenario 1), or when the covariates are proportions under the 
heterogeneity scenarios (Scenarios 2 and 3). The score test achieves lower power than the 
LRT for the other scenarios and the difference in power increases with increasing 
parameters. Note that in the One Random Effects scenario (Scenario 3) we generate data 
assuming only one of the between-study variances is non-zero but test the null hypothesis 
that both between-study variances and the SNP main effect is zero. Hence, our analysis 
model is not the same as we generate the data. However, we observe similar results in the 
scenario 3 as in the Two Random Effects scenario (Scenario 2), demonstrating our 
proposed model is robust to such a situation. 
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We derived the score functions and information matrix with respect to both 𝜏 and 𝜏2 
(Appendix E), and showed that both score tests follow a 𝜒2 distribution with degrees of 
freedom determined by the number of parameters we specify to be equal to 0 under the 
null hypothesis. We showed that the type I error rates are inflated due to some influential 
points with small variances and relatively large effect sizes that cause inflation in the 
score statistics. This inflation led us to use the empirical null distribution that yields well 
controlled type I error rates (Appendix F).  
 
Future work may identify alternative ways to correct the null distribution. One possible 
alternative to the empirical null distribution approach is a shrinkage estimation for 
dispersions. An Empirical Bayes shrinkage method has been proposed and implemented 
to shrink a dispersion parameter in the context of RNA-seq data analysis (Wu, Wang, and 
Wu 2013; Love, Huber, and Anders 2014). If the estimated variances shrink towards a 
mean estimate we might be able to avoid the inflation in the score statistics due to the 
influential points with small variances.   
 
Although the proposed test has slightly lower power than the LRT approach developed in 
chapter 3, the computational advantage (Table 4.2) is substantial despite the need for the 
empirical null distribution. With this evident computational efficiency, one might suggest 
a two-stage approach such that one uses the score test for genome-wide scan and 
computes the LRT for any detected significant SNPs. This can be an alternative to utilize 
both score and LRT statistics for large data analysis such as genome-wide studies.   
109 
 
 
 
In summary, we proposed a score test approach for the meta-analysis of potentially 
heterogeneous studies. Because it estimates the parameters only under the null 
hypothesis, the computational advantage of the score test is evident and the estimation of 
the test statistic is rapid. Given the power of the score test is similar to that of the LRT for 
some of the scenarios especially when the covariates are proportions and with its 
computational advantage, the score test with some modification can be an alternative 
approach in jointly testing the effect size and the heterogeneity for the meta-analysis of 
heterogeneous studies.  
 
 
Table 4.2 Average computational time (in minutes) for the calculation of the LRT and the 
score test statistics for 10,000 simulations 
 Number of Studies (N) 
(In minutes) 10 20 50 100 
LRT 17.1 20.4 44.7 171.8 
Score 1.3 1.2 1.4 2.5 
We used Intel®  Xeon®  Processor E5-2650 v2 (20M Cache, 2.60 GHz) for this 
comparative computational time analysis. 
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Chapter 5 Conclusion and Future Work 
 
Meta-analysis is an effective statistical approach in genetic association studies. It has 
been successful in identifying novel variants. However, until recently, the lack of 
diversity of ancestry in GWA studies has led to the application of meta-analysis primarily 
for single ancestry, predominantly European-descent population studies. With increasing 
number of GWAS in non-European-ancestry populations, we believe that properly 
aggregating evidence from multiple studies with ethnically diverse populations would 
provide a great opportunity to expand our understanding of disease etiology. New 
statistical approaches are required to tackle challenges in such meta-analyses.  
 
 In this dissertation, we proposed a statistical strategy and two new meta-analytic models 
in the context of meta-analysis of potentially heterogeneous studies. In chapter 2, we 
proposed a two-stage approach to account for heterogeneity in trans-ethnic meta-analysis 
in which we clustered studies with cohort-specific ancestry information prior to meta-
analysis using a hierarchical clustering algorithm. In the extensive simulation study, we 
compared this approach to a no clustering (one-stage), evaluating type I error and power 
of these two strategies. We showed that the two-stage approach could be an effective and 
efficient intermediate step in meta-analysis to account for heterogeneity due to studies 
with varying ancestries. From our simulation studies, the two-stage approach is robust to 
incorrect clustering by taking a sub-optimal dissimilarity value for the threshold. 
However, the currently implemented fixed-threshold approach is subjective and might be 
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potentially prone to incorrect clustering.  Therefore, one potential future direction for this 
work is to develop a better, more objective mechanism or measurement, such as a data-
driven approach to find an optimal threshold for clustering.  
 
The source of heterogeneity in meta-analysis is not limited to the difference in genetic 
backgrounds of samples. Heterogeneity could arise from different study designs or 
environmental exposures. Incorporating such heterogeneity in meta-analysis is crucial. In 
chapters 3 and 4, we developed new meta-analytic models that could be used in the meta-
analysis of heterogeneous studies. In chapter 3, we extended the Han and Eskin (B. Han 
and Eskin 2011) random-effects approach under a meta-regression framework and 
developed a new likelihood ratio test (LRT) statistic to accommodate multiple random 
effects. We showed that our new LRT was comparable to the other methods in the 
simulation study, especially when heterogeneity in effect sizes was present. The new 
LRT was successfully applied in a meta-analysis of genome-wide association studies 
from the Meta-Analyses of Glucose- and Insulin- related traits Consortium with a log-
transformed fasting insulin with study-level mean body mass index and age as covariates. 
The new LRT was developed for common genetic variant analyses. Because of 
increasing availability of rare variant analyses as described in chapter 1.1 and the 
advantage of multiple ancestries for meta-analysis of rare variants association tests 
(Mensah-Ablorh et al. 2016), future work may involve the extension of our approach to 
rare variant meta-analyses of potentially heterogeneous studies.   
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In chapter 4, we developed a score test statistic in the same context as in chapter 3, 
hoping to improve computational efficiency and numerical stability. We observed that the 
type I error rates using an asymptotic distribution were inflated due to some influential 
points with small variances and relatively large effect sizes that caused inflated score 
statistics. The empirical null distribution yielded controlled type I error rates; however, 
power for the score test was lower than for the corrected LRT in chapter 3. A possible 
alternative to the empirical null distribution we implemented is a shrinkage approach. 
Empirical Bayes shrinkage methods have been proposed and implemented to shrink a 
dispersion parameter in the context of RNA-seq data analysis (Wu, Wang, and Wu 2013; 
Love, Huber, and Anders 2014). If the estimated variances shrink towards a mean 
estimate we might be able to avoid the inflation in the score statistics due to the 
influential points with small variances.  
 
We have described three projects related to the meta-analysis of heterogeneous studies 
and demonstrated that the proposed approach and models could effectively and 
efficiently aggregate the evidence from heterogeneous studies and improve the ability to 
detect genetic variants with weaker associations that could have been missed in the 
traditional genetic association studies.  
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Appendices 
 
Appendix A Derivation of Maximum Likelihood Estimators for 𝜷 and 𝝉𝒊
𝟐 
 
The log-likelihood function of the likelihood we obtained in chapter 3.2.1.2 under the 
union of 𝜽 ∈ 𝜣𝟎 ∪ 𝜣𝟏 is 
 
𝑙 = 𝐶 −
1
2
𝑙𝑛|𝑾| −
1
2
(𝒃 − 𝜷)′𝑾−1(𝒃 − 𝜷),   (1) 
 
where 𝐶 = −
1
𝑘
𝑙𝑛(√2𝜋) and 𝑾 = 𝒁𝜮𝒗𝒁
′ + 𝑹 and 
𝒃 = 𝑁 by 1 vector of observed effects from 𝑁 studies, 
𝜷 = 𝑁 by 1 vector of the unknown true effect size of 𝑁 studies, 
𝒁 = 𝑁 by r design matrix for covariates for unknown random effects, 
𝜮𝒗= r by r diagonal covariance matrix for unknown random effects, 
𝑹 = 𝑁 by 𝑁 of a diagonal residual covariance matrix for 𝑁 studies. 
 
The maximum likelihood estimators (MLEs) of the true effect size 𝛽 and the variances of 
the random effects 𝜏𝑗
2, for 𝑗 = 1,… , 𝑟, can be derived by setting the first derivative of the 
log-likelihood function with respect to the parameters to zero. 
 
The MLE of the 𝛽 is  
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𝜕𝑙
𝜕𝛽
= (𝒃 − 𝜷)′𝑾−1𝑱1 ≡ 0 
⟺  𝒃′𝑾−1𝑱1 = ?̂?𝑱1
′ 𝑾−1𝑱1 
⟺  ?̂? = 𝒃′𝑾−1𝑱1(𝑱1
′ 𝑾−1𝑱1)
−1 
where 𝑱1 is a N dimensional vector of 1’s. 
 
The MLE of the 𝜏𝑗
2 is  
𝜕𝑙
𝜕𝜏𝑗
2 = −
1
2
(𝑡𝑟(𝑾−1
𝜕𝑾
𝜕𝜏𝑗
2)) −
1
2
((𝒃 − ?̂?)
′ 𝜕𝑾−1
𝜕𝜏𝑗
2 (𝒃 − ?̂?)) ≡ 0 
⟺  −
1
2
(𝑡𝑟(𝑾−1𝒛𝑗𝒛𝑗
′)) −
1
2
((𝒃 − ?̂?)
′
(−𝑾−𝟏
𝜕𝑾
𝜕𝜏𝑗
2 𝑾
−1) (𝒃 − ?̂?)) = 0 
⟺  −
1
2
(𝑡𝑟(𝑾−1𝒛𝑗𝒛𝑗
′)) −
1
2
((𝒃 − ?̂?)
′
(−𝑾−1𝒛𝑗𝒛𝑗
′𝑾−1)(𝒃 − ?̂?)) = 0 
⟺ 𝑡𝑟(𝑾−1𝒛𝑗𝒛𝑗
′) − (𝒃 − ?̂?)
′
(𝑾−1𝒛𝑗𝒛𝑗
′𝑾−1)(𝒃 − ?̂?) = 0 
 
A closed-form solution for the maximum likelihood estimator of the true effect size 𝛽 can 
be obtained, however, there is no closed-form for the variances of the random 
effects 𝜏𝑗
2, for 𝑗 = 1,… , 𝑟. 
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Appendix B Candidate “Correct” Null Distribution Comparison  
Table B.1 Type I error comparison for candidate “corrected” null distribution for N=10 
N=10 
α levels 
Study 
Characteri
stics a 
𝑎𝜒1
2 + 𝑏 b 𝑎𝜒1
2 + 𝑏 c 𝑎𝜒2
2 + 𝑏 b 𝑎𝜒2
2 + 𝑏 c 𝑎𝜒3
2 + 𝑏 b 𝑎𝜒3
2 + 𝑏 c 
𝑎𝜒1
2 +
𝑏𝜒2
2 +
𝑐𝜒3
2 d 
𝒂𝝌𝟏
𝟐 +
𝒃𝝌𝟐
𝟐 + 𝒄 
b 
𝑎𝜒1
2 +
𝑏𝜒3
2 + 𝑐 b 
α=0.01 
CONT+ 
CONT 
0.008 0.008 0.011 0.011 0.012 0.012 0.011 0.009 0.009 
DICH+ 
DICH 
0.009 0.009 0.012 0.012 0.014 0.013 0.012 0.010 0.010 
PROP+ 
PROP 
0.009 0.009 0.013 0.012 0.014 0.013 0.012 0.010 0.010 
CONT+ 
DICH 
0.009 0.009 0.012 0.012 0.014 0.013 0.010 0.009 0.009 
α=0.001 
CONT+ 
CONT 
0.0006 0.0006 0.0014 0.0013 0.0020 0.0019 0.0011 0.0008 0.0007 
DICH+ 
DICH 
0.0006 0.0006 0.0015 0.0015 0.0023 0.0021 0.0012 0.0009 0.0009 
PROP+ 
PROP 
0.0008 0.0008 0.0017 0.0017 0.0025 0.0022 0.0012 0.0010 0.0010 
CONT+ 
DICH 
0.0008 0.0008 0.0016 0.0016 0.0024 0.0022 0.0011 0.0009 0.0009 
a Types of study characteristics as the sources of heterogeneity; CONT-Continuous, DICH-dichotomous, PROP-proportion, 
CONT+DICH-a combination of continuous and dichotomous covariates. 
Scaled-shifted parameters (a, b and/or c) are estimated using b a regression, c method of moments, and d a numerical method.  
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Table B.2 Type I error comparison for candidate “corrected” null distribution for N=20 
N=20 
α levels 
Study 
Characteri
stics a 
𝑎𝜒1
2 + 𝑏 b 𝑎𝜒1
2 + 𝑏 c 𝑎𝜒2
2 + 𝑏 b 𝑎𝜒2
2 + 𝑏 c 𝑎𝜒3
2 + 𝑏 b 𝑎𝜒3
2 + 𝑏 c 
𝑎𝜒1
2 +
𝑏𝜒2
2 +
𝑐𝜒3
2 d 
𝒂𝝌𝟏
𝟐 +
𝒃𝝌𝟐
𝟐 + 𝒄 
b 
𝑎𝜒1
2 +
𝑏𝜒3
2 + 𝑐 b 
α=0.01 
CONT+ 
CONT 
0.008 0.008 0.012 0.011 0.013 0.013 0.011 0.010 0.009 
DICH+ 
DICH 
0.008 0.008 0.011 0.011 0.013 0.012 0.011 0.009 0.009 
PROP+ 
PROP 
0.009 0.009 0.013 0.013 0.014 0.014 0.012 0.010 0.010 
CONT+ 
DICH 
0.010 0.010 0.013 0.013 0.014 0.014 0.011 0.010 0.010 
α=0.001 
CONT+ 
CONT 
0.0005 0.0005 0.0014 0.0014 0.0021 0.0020 0.0012 0.0009 0.0008 
DICH+ 
DICH 
0.0006 0.0006 0.0015 0.0014 0.0021 0.0019 0.0012 0.0009 0.0009 
PROP+ 
PROP 
0.0007 0.0007 0.0018 0.0018 0.0027 0.0025 0.0013 0.0011 0.0010 
CONT+ 
DICH 
0.0009 0.0009 0.0020 0.0020 0.0028 0.0026 0.0012 0.0010 0.0010 
a Types of study characteristics as the sources of heterogeneity; CONT-Continuous, DICH-dichotomous, PROP-proportion, 
CONT+DICH-a combination of continuous and dichotomous covariates. 
Scaled-shifted parameters (a, b and/or c) are estimated using b a regression, c method of moments, and d a numerical method.  
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Table B.3 Type I error comparison for candidate “corrected” null distribution for N=50 
N=50 
α levels 
Study 
Characteri
stics a 
𝑎𝜒1
2 + 𝑏 b 𝑎𝜒1
2 + 𝑏 c 𝑎𝜒2
2 + 𝑏 b 𝑎𝜒2
2 + 𝑏 c 𝑎𝜒3
2 + 𝑏 b 𝑎𝜒3
2 + 𝑏 c 
𝑎𝜒1
2 +
𝑏𝜒2
2 +
𝑐𝜒3
2 d 
𝒂𝝌𝟏
𝟐 +
𝒃𝝌𝟐
𝟐 + 𝒄 
b 
𝑎𝜒1
2 +
𝑏𝜒3
2 + 𝑐 b 
α=0.01 
CONT+ 
CONT 
0.008 0.008 0.012 0.012 0.013 0.013 0.012 0.010 0.009 
DICH+ 
DICH 
0.008 0.008 0.012 0.012 0.014 0.013 0.011 0.010 0.010 
PROP+ 
PROP 
0.009 0.009 0.012 0.012 0.013 0.013 0.011 0.009 0.009 
CONT+ 
DICH 
0.009 0.009 0.013 0.012 0.014 0.013 0.011 0.010 0.010 
α=0.001 
CONT+ 
CONT 
0.0006 0.0006 0.0014 0.0014 0.0022 0.0021 0.0012 0.0009 0.0009 
DICH+ 
DICH 
0.0006 0.0006 0.0016 0.0016 0.0024 0.0022 0.0013 0.0009 0.0009 
PROP+ 
PROP 
0.0007 0.0007 0.0017 0.0017 0.0026 0.0024 0.0012 0.0009 0.0009 
CONT+ 
DICH 
0.0007 0.0007 0.0019 0.0018 0.0028 0.0025 0.0010 0.0008 0.0008 
a Types of study characteristics as the sources of heterogeneity; CONT-Continuous, DICH-dichotomous, PROP-proportion, 
CONT+DICH-a combination of continuous and dichotomous covariates. 
Scaled-shifted parameters (a, b and/or c) are estimated using b a regression, c method of moments, and d a numerical method. 
 
  
  
 
1
1
8
 
Table B.4 Type I error comparison for candidate “corrected” null distribution for N=100 
N=100 
α levels 
Study 
Characteri
stics a 
𝑎𝜒1
2 + 𝑏 b 𝑎𝜒1
2 + 𝑏 c 𝑎𝜒2
2 + 𝑏 b 𝑎𝜒2
2 + 𝑏 c 𝑎𝜒3
2 + 𝑏 b 𝑎𝜒3
2 + 𝑏 c 
𝑎𝜒1
2 +
𝑏𝜒2
2 +
𝑐𝜒3
2 d 
𝒂𝝌𝟏
𝟐 +
𝒃𝝌𝟐
𝟐 + 𝒄 
b 
𝑎𝜒1
2 +
𝑏𝜒3
2 + 𝑐 b 
α=0.01 
CONT+ 
CONT 
0.008 0.008 0.012 0.011 0.013 0.013 0.011 0.010 0.009 
DICH+ 
DICH 
0.009 0.009 0.012 0.012 0.014 0.013 0.012 0.010 0.010 
PROP+ 
PROP 
0.009 0.009 0.012 0.012 0.014 0.013 0.012 0.010 0.010 
CONT+ 
DICH 
0.010 0.010 0.013 0.013 0.014 0.014 0.011 0.010 0.010 
α=0.001 
CONT+ 
CONT 
0.0005 0.0005 0.0012 0.0012 0.0019 0.0018 0.0010 0.0007 0.0007 
DICH+ 
DICH 
0.0005 0.0005 0.0013 0.0013 0.0020 0.0019 0.0010 0.0008 0.0008 
PROP+ 
PROP 
0.0007 0.0007 0.0016 0.0016 0.0024 0.0022 0.0011 0.0009 0.0008 
CONT+ 
DICH 
0.0008 0.0008 0.0018 0.0018 0.0028 0.0026 0.0011 0.0009 0.0009 
a Types of study characteristics as the sources of heterogeneity; CONT-Continuous, DICH-dichotomous, PROP-proportion, 
CONT+DICH-a combination of continuous and dichotomous covariates. 
Scaled-shifted parameters (a, b and/or c) are estimated using b a regression, c method of moments, and d a numerical method. 
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Appendix C Type I Error Rates from the Corrected Null Distribution in Two 
Additional Simulation Situations  
 
After carefully following these steps and comparing the candidate distributions 
(Appendix B), we select the following mixture distribution, 𝑎𝜒1
2 + 𝑏𝜒22
2 + 𝑐, that shows 
anti-conservative but well-controlled type I error rates. Now we want to show that how it 
performs in two different simulation situations.  
 
C.1 Varying Within-Study Variance  
In simulation study, we generate data from 𝑏𝑖~𝑁(0, 𝜎𝑖
2) and 𝜎𝑖
2~𝜒1
2. In GWAS, different 
MAFs may affect the standard errors of effect size estimates of SNPs. In order to mimic 
and to explore how the corrected null distribution would work in such a situation, we 
vary 𝜎𝑖
2 values when we generate data. We generate data using 10*𝜎𝑖
2 and 0.1*𝜎𝑖
2, and 
evaluate type I error rates from the corrected null distribution.  
   
 
1
2
0
 
Table C.1 Type I error rates varying within-study variance for N=50 
  1*𝜎𝑖
2 10*𝜎𝑖
2 0.1*𝜎𝑖
2 
α levels 
Study 
Characteris
tics a 
Type I 
error 
95% C.I. 
LL b 
95% C.I. 
UL b 
Type I 
error 
95% C.I. 
LL b 
95% C.I. 
UL b 
Type I 
error 
95% C.I. 
LL b 
95% C.I. 
UL b 
α=0.01 
CONT+ 
CONT 0.010 0.009 0.010 0.009 0.009 0.010 0.009 0.008 0.010 
DICH+ 
DICH 0.010 0.009 0.010 0.010 0.009 0.010 0.009 0.009 0.010 
PROP+ 
PROP 0.009 0.009 0.010 0.010 0.009 0.010 0.009 0.009 0.010 
CONT+ 
DICH 0.010 0.009 0.010 0.007 0.007 0.008 0.008 0.008 0.009 
α=0.001 
CONT+ 
CONT 0.0009 0.0007 0.0010 0.0008 0.0006 0.0010 0.0008 0.0006 0.0010 
DICH+ 
DICH 0.0009 0.0007 0.0011 0.0009 0.0007 0.0011 0.0009 0.0007 0.0010 
PROP+ 
PROP 0.0009 0.0007 0.0011 0.0009 0.0007 0.0011 0.0009 0.0007 0.0010 
CONT+ 
DICH 0.0008 0.0006 0.0010 0.0007 0.0005 0.0008 0.0008 0.0006 0.0010 
a Types of study characteristics as the sources of heterogeneity; CONT-Continuous, DICH-dichotomous, PROP-proportion, 
CONT+DICH-a combination of continuous and dichotomous covariates. 
b 95% C.I. LL-95% confidence interval lower limit; 95% C.I. UL-95% confidence interval upper limit. 
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C.2 Varying Z distribution 
We explore how the corrected null distribution would work when we evaluate the test statistic using study characteristic 
measures simulated from different distribution. We examine when the study characteristics are continuous+continuous and 
dichotomous+dichotomous. The original continuous covariate measures are generated from 𝑁(0, 𝜎𝑧
2), 𝜎𝑧
2=1. We vary the 
variance 𝜎𝑧
2 to 0.09 and 0.25. The original dichotomous covariate measures are generated from Bernoulli(0.5). We vary the 
probability for the two dichotomous covariates to (0.3,0.6), and (0.1,0.9).  
 
Table C.2 Type I error rates varying Z distribution when covariates are continuous 
  N=10 N=20 N=50 N=100 
α 
levels 
𝜎𝑧
2 a 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
α= 
0.01 
0.09 0.008 0.008 0.009 0.009 0.009 0.010 0.010 0.009 0.010 0.010 0.009 0.010 
0.25 0.009 0.008 0.009 0.009 0.009 0.010 0.010 0.009 0.010 0.010 0.009 0.010 
α= 
0.001 
0.09 0.0007 0.0005 0.0008 0.0009 0.0007 0.0010 0.0009 0.0007 0.0011 0.0007 0.0006 0.0009 
0.25 0.0008 0.0006 0.0009 0.0009 0.0007 0.0010 0.0009 0.0007 0.0011 0.0007 0.0005 0.0009 
a The variance of normal distribution for continuous covariates. 
b 95% C.I. LL-95% confidence interval lower limit; 95% C.I. UL-95% confidence interval upper limit. 
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Table C.3 Type I error rates varying Z distribution when covariates are dichotomous 
  N=10 N=20 N=50 N=100 
α 
levels 
𝑝1, 𝑝2 
a 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
Type I 
error 
95% CI 
LL b 
95% CI 
UL b 
α= 
0.01 
0.3,0.6 0.009 0.009 0.010 0.010 0.010 0.011 0.010 0.010 0.011 0.010 0.009 0.011 
0.1,0.9 NA NA NA NA NA NA 0.009 0.009 0.010 0.010 0.009 0.010 
α= 
0.001 
0.3,0.6 0.0009 0.0007 0.0011 0.0010 0.0008 0.0012 0.0009 0.0007 0.0011 0.0008 0.0006 0.0010 
0.1,0.9 NA NA NA NA NA NA 0.0008 0.0006 0.0009 0.0008 0.0006 0.0009 
a The probability of Bernoulli distribution for two dichotomous covariates. 
b 95% C.I. LL-95% confidence interval lower limit; 95% C.I. UL-95% confidence interval upper limit. 
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Appendix D Derivation of Score Functions and Information Matrix for Score Test 
 
We derive the score function of our parameters of interest, 𝛽,  𝜏1
2, … , 𝜏𝑟
2, and their variance 
and covariance by the first and second derivatives of the log-likelihood in the equation 
(1) in Appendix A with respect to the parameters. For our convenience, we replace 
(𝒃 − 𝜷) by ?̃?. The score function, and its variance and covariance are obtained as follows 
𝑢(𝜃𝑝) =
𝜕𝑙
𝜕𝜃𝑝
 , 
𝐼(𝜃𝑝𝑞) = −𝐸 [
𝜕2𝑙
𝜕𝜃𝑝𝜕𝜃𝑞
], 
 
where 𝜃𝑝, 𝜃𝑞 ∈ 𝜃 = (𝛽,  𝜏1
2, … , 𝜏𝑟
2). Note that because 𝑹 and 𝜮𝒗 are diagonal matrices, the 
transpose of the covariance matrices are the same as the corresponding covariance 
matrices; 𝑹′ = 𝑹, 𝜮𝒗
′ = 𝜮𝒗,𝑾
′ = [𝒁𝜮𝒗𝒁
′ + 𝑹]′ = 𝒁𝜮𝒗
′ 𝒁′ + 𝑹′ = 𝒁𝜮𝒗𝒁
′ + 𝑹 = 𝑾. 
 
Now the score functions of our parameters are 
𝑢(𝛽) =
𝜕𝑙
𝜕𝛽
=
𝜕
𝜕𝛽
[𝐶 −
1
2
𝑙𝑛|𝑾|] +
𝜕
𝜕𝛽
[−
1
2
?̃?′𝑾−1?̃?] 
= 𝟎 +
𝜕
𝜕𝛽
[−
1
2
?̃?′𝑾−1?̃?] 
= −
1
2
?̃?{[−𝑱1
′ 𝑾−1]′ 𝑾−1(−𝑱1)} 
= ?̃?′𝑾−1𝑱1 
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𝑢(𝜏𝑗
2) =
𝜕𝑙
𝜕𝜏𝑗
2 =
𝜕
𝜕𝜏𝑗
2 [𝐶 −
1
2
𝑙𝑛|𝑾|] +
𝜕
𝜕𝜏𝑗
2 [−
1
2
?̃?′𝑾−1?̃?] 
= 𝟎 −
1
2
[𝑡𝑟 (𝑾−1
𝜕𝑾
𝜕𝜏𝑗
2)] −
1
2
(?̃?′
𝜕𝑾−1
𝜕𝜏𝑗
2 ?̃?)  by 𝜕(𝑙𝑛|𝑿|) = 𝑡𝑟(𝑿
−1 𝜕𝑿)′ 
= −
1
2
[𝑡𝑟(𝑾−1𝒛𝒋𝒛𝒋
′)] −
1
2
[?̃?′ (−𝑾−1
𝜕𝑾
𝜕𝜏𝑗
2 𝑾
−1) ?̃?]  by 𝜕𝑿−1 = −𝑿−1(𝜕𝑿)𝑿−1 
= −
1
2
𝑡𝑟(𝑾−1𝒛𝒋𝒛𝒋
′) +
1
2
?̃?′(𝑾−1𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃? 
 
And the diagonal and off-diagonal elements of the information matrix are the second 
derivatives of the log-likelihood function as follows 
−𝐸 [
𝜕2𝑙
𝜕𝛽2
] = −𝐸 [
𝜕𝑢(𝛽)
𝜕𝛽
] = −𝐸[−𝑱1
′ 𝑾−1𝑱1] = 𝑱1
′ 𝑾−1𝑱1 
 
−𝐸 [
𝜕2𝑙
𝜕𝜏𝑖
2𝜕𝜏𝑗
2] = −𝐸 [
𝜕𝑢(𝜏𝑗
2)
𝜕𝜏𝑖
2 ] = −𝐸 [
𝜕𝑢(𝜏𝑖
2)
𝜕𝜏𝑗
2 ] 
= −𝐸 [
𝜕
𝜕𝜏𝑗
2 [−
1
2
𝑡𝑟(𝑾−1𝒛𝒊𝒛𝒊
′) +
1
2
?̃?′(𝑾−1𝒛𝒊𝒛𝒊
′𝑾−𝟏)?̃?]] 
= −𝐸 [−
1
2
𝜕
𝜕𝜏𝑗
2 𝑡𝑟(𝑾
−𝟏𝒛𝒊𝒛𝒊
′) +
1
2
?̃?′ (
𝜕𝑾−𝟏
𝜕𝜏𝑗
2 𝒛𝒊𝒛𝒊
′𝑾−𝟏 + 𝑾−𝟏𝒛𝒊𝒛𝒊
′ 𝜕𝑾
−𝟏
𝜕𝜏𝑗
2 ) ?̃?] 
= −𝐸 [−
1
2
𝑡𝑟 (
𝜕𝑾−𝟏
𝜕𝜏𝑗
2 𝒛𝒊𝒛𝒊
′) +
1
2
?̃?′ (
𝜕𝑾−𝟏
𝜕𝜏𝑗
2 𝒛𝒊𝒛𝒊
′𝑾−𝟏 + 𝑾−𝟏𝒛𝒊𝒛𝒊
′ 𝜕𝑾
−𝟏
𝜕𝜏𝑗
2 ) ?̃?] 
= −𝐸 [−
1
2
𝑡𝑟(−𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′)
+
1
2
?̃?′(−𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏 − 𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃?] 
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= −
1
2
𝐸[𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′)] +
1
2
𝐸[?̃?′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏)?̃?]
+
1
2
𝐸[?̃?′(𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃?] 
= −
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′) +
1
2
𝐸 [𝑡𝑟 ((𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏)?̃??̃?′)]
+
1
2
𝐸 [𝑡𝑟 ((𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃??̃?′)] 
= −
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′) +
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏)𝑾
+
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)𝑾 
= −
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′) +
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒊𝒛𝒊
′)
+
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏𝒛𝒋𝒛𝒋
′) 
=
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒊𝒛𝒊
′𝑾−𝟏𝒛𝒋𝒛𝒋
′) 
If 𝑖 = 𝑗 then  
−𝐸 [
𝜕2𝑙
𝜕(𝜏𝑗
2)
2] = −𝐸 [
𝜕𝑢(𝜏𝑗
2)
𝜕𝜏𝑗
2 ] =
1
2
𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒋𝒛𝒋
′) 
 
 
−𝐸 [
𝜕𝑢(𝛽)
𝜕𝜏𝑗
2 ] = −𝐸 [
𝜕𝑢(𝜏𝑗
2)
𝜕𝛽
] = −𝐸[−?̃?′(𝑾−1𝒛𝒋𝒛𝒋
′𝑾−𝟏)𝑱1] = 0 
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Appendix E Derivation of Score Function of 𝝉𝒋 and its Variance 
 
We use the same log-likelihood function as in Appendix A. In order to obtain the 
information matrix 𝑰(𝜽), we show the first and second derivatives of the log-likelihood 
with respect to 𝜏𝑗. For our convenience, we replace (𝒃 − 𝜷) by ?̃?. We can obtain a score 
function by the first derivative of 𝑙 with respect to 𝜏𝑗 is  
 
𝜕𝑙
𝜕𝜏𝑗
= −
1
2
(𝑡𝑟(𝑾−1
𝜕𝑾
𝜕𝜏𝑗
)) −
1
2
(?̃?′ 
𝜕𝑾−1
𝜕𝜏𝑗
 ?̃?) 
= −
1
2
(𝑡𝑟(𝑾−1
𝜕𝑾
𝜕𝜏𝑗
)) −
1
2
(?̃?′ (−𝑾−1
𝜕𝑾
𝜕𝜏𝑗
𝑾−1) ?̃?) 
= −
1
2
(𝑡𝑟(𝑾−12𝒛𝑗𝜏𝑗𝒛𝑗
′)) −
1
2
(?̃?′(−𝑾−12𝒛𝑗𝜏𝑗𝒛𝑗
′𝑾−1) ?̃?) 
= −𝑡𝑟(𝑾−1𝒛𝑗𝒛𝑗
′)𝜏𝑗 + ?̃?
′(𝑾−1𝒛𝑗𝒛𝑗
′𝑾−1) ?̃? 𝜏𝑗 . 
 
The first derivative of 𝑙 with respect to 𝜏𝑗 evaluated at 𝜏𝑗 = 0 contains no 
information: 
𝜕𝑙
𝜕𝜏𝑗
|
𝜏𝑗=0
= 0. However, the second derivative of 𝑙 with respect to 𝜏𝑗 
evaluated at 𝜏𝑗 = 0 is not 0 and is proportional to the first derivative of 𝑙 with respect 
to 𝜏𝑗
2 evaluated at 𝜏𝑗 = 0 (Dupuis, Siegmund, and Yakir 2007a).  
 
The second derivative of 𝑙 with respect to 𝜏𝑗 is 
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𝜕2𝑙
𝜕(𝜏𝑗)2
= −
𝜕
𝜕𝜏𝑗
[𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′)𝜏𝑗] +
𝜕
𝜕𝜏𝑗
[?̃?′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃? 𝜏𝑗] 
= −𝑡𝑟 (
𝜕𝑾−𝟏
𝜕𝜏𝑗
𝒛𝒋𝒛𝒋
′) 𝜏𝑗 − 𝑡𝑟(𝑾
−𝟏𝒛𝒋𝒛𝒋
′)
𝜕𝝉𝒋
𝜕𝜏𝑗
 
+?̃?′ (
𝜕𝑾−𝟏
𝜕𝜏𝑗
𝒛𝒋𝒛𝑗
′𝑾−𝟏 + 𝑾−𝟏𝒛𝒋𝒛𝒋
′ 𝜕𝑾
−𝟏
𝜕𝜏𝑗
) ?̃?𝜏𝑗 + ?̃?
′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃?
𝜕𝜏𝒋
𝜕𝜏𝑗
 
= −𝑡𝑟 (−𝑾−𝟏
𝜕𝑾
𝜕𝜏𝑗
𝑾−𝟏𝒛𝒋𝒛𝒋
′) 𝜏𝑗 − 𝑡𝑟(𝑾
−𝟏𝒛𝒋𝒛𝒋
′) 
+?̃?′ (−𝑾−𝟏
𝜕𝑾
𝜕𝜏𝑗
𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏 + 𝑾−𝟏𝒛𝒋𝒛𝒋
′−𝑾−𝟏
𝜕𝑾
𝜕𝜏𝑗
𝑾−𝟏)  ?̃?𝜏𝑗 + ?̃?
′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃? 
= −𝑡𝑟(−𝑾−𝟏2𝒛𝒋𝜏𝑗𝒛𝒋
′𝑾−𝟏𝒛𝒋𝒛𝒋
′)𝜏𝑗 − 𝑡𝑟(𝑾
−𝟏𝒛𝒋𝒛𝒋
′) 
+?̃?′(−𝑾−𝟏2𝒛𝒋𝜏𝑗𝒛𝒋
′𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏 +  𝑾−𝟏𝒛𝒋𝒛𝒋
′−𝑾−𝟏2𝒛𝒋𝜏𝑗𝒛𝒋
′𝑾−𝟏) ?̃?𝜏𝑗
+ ?̃?′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃? 
= 2𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒋𝒛𝒋
′)𝜏𝑗
2 − 4?̃?′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏) ?̃? 𝜏𝑗
2 − 𝑡𝑟(𝑾−𝟏𝒛𝒋𝒛𝒋
′)
+ ?̃?′(𝑾−𝟏𝒛𝒋𝒛𝒋
′𝑾−𝟏)?̃? 
 
This second derivative preserves the property that 𝐸 [
𝜕2𝑙
𝜕(𝜏𝑗)
2] = 0 and carries information 
evaluated at 𝜏𝑗 = 0 such that 
𝜕2𝑙
𝜕(𝜏𝑗)
2|
𝜏𝑗=0
= −𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒊𝒛𝒊
′) + ?̃?′(𝑾𝟎
−𝟏𝒛𝒊𝒛𝒊
′𝑾𝟎
−𝟏)?̃?, 
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where 𝑾𝟎 = 𝒁𝜮𝒗𝟎𝒁
′ + 𝑹,  𝜮𝒗𝟎 = 𝜮𝒗|𝜏𝑗=0,  𝜮𝒗 = 𝑣𝑎𝑟[𝒗] = [
𝜏1
2 ⋯ 0
⋮ ⋱ ⋮
0 ⋯ 𝜏𝑟
2
]. Therefore, we 
take the second derivative of 𝑙 with respect to 𝜏𝑗 for our score function 𝑢𝜏𝑗0=
𝜕2𝑙
𝜕(𝜏𝑗)
2|
𝜏𝑗=0
 
and derive its variance by 𝐸 [𝑢𝜏𝑗0𝑢𝜏𝑗0
′ ]. 
 
The derivation of the variance of the score function 𝑉𝑎𝑟 [𝑢𝜏𝑗0] follows 
𝑉𝑎𝑟 [𝑢𝜏𝑗0] = 𝐸 [𝑢𝜏𝑗0𝑢𝜏𝑗0
′ ] 
= E [{𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
2
− 2𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?
+ ?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃??̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?] 
= {𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
2
− 2𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏𝐸[?̃??̃?′])
+ 𝐸[?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃??̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?] 
= {𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
2
− 2𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏𝑾𝟎)
+ 𝐸[?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃??̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?] 
= −{𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
2
+ 𝐸[?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃??̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?] 
 
Now we have two terms for the variance of the score function and the derivation of the 
second term is not trivial. Kumar (Kumar 1973) and Misra (Misra 1972) derived the 
expectation of products of quadratic forms including the expectation of a product of two 
quadratic forms such that 𝐸[?̃?′𝑨1?̃??̃?
′𝑨2?̃?] = 2𝑡𝑟(𝑨1𝑨2) + 𝑡𝑟(𝑨1)𝑡𝑟(𝑨2). 
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The second term of the variance of the score function can be re-written as follows 
𝐸[?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃??̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?] 
= 𝐸 [?̃?′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐?̃??̃?′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐?̃?] 
Let ?̃? = ?̃?𝑾𝟎
−
𝟏
𝟐 ~ 𝑵(𝟎,  𝑰) and 𝑨 = 𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
′𝑾𝟎
−
𝟏
𝟐  then it can be re-written in the form of 
𝐸[?̃?′𝑨?̃??̃?′𝑨?̃?]. 
 
Therefore, as 𝐸[?̃?′𝑨?̃??̃?′𝑨?̃?] = 2𝑡𝑟(𝑨𝑨) + 𝑡𝑟(𝑨)𝑡𝑟(𝑨),  
𝐸 [?̃?′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐?̃??̃?′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐?̃?] 
= 2𝑡𝑟 (𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
′𝑾𝟎
−
𝟏
𝟐𝑾𝟎
−
𝟏
𝟐𝒛𝒋𝒛𝒋
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𝟐𝒛𝒋𝒛𝒋
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𝟏
𝟐)}
𝟐
 
= 2𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′) + {𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
𝟐
 
 
Finally, the variance of the score function 𝑢𝜏𝑗0  is 
𝑉𝑎𝑟 [𝑢𝜏𝑗0] = 𝐸 [𝑢𝜏𝑗0𝑢𝜏𝑗0
′ ] 
= −{𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
2
+ 𝐸[?̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃??̃?′(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏)?̃?] 
= −{𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
2
+ 2𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′) + {𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′)}
𝟐
 
= 2𝑡𝑟(𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′𝑾𝟎
−𝟏𝒛𝒋𝒛𝒋
′) 
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Appendix F Investigation on Inflated Score Test Statistic and Search for a Null 
Distribution that control Type I Error Rates 
F.1 Univariate Score Statistics and Type I error rates 
In order to track potential issues more effectively, we broke down the 3-df score statistic 
into three univariate score statistics. As shown in Table F.1, the type I error rates for 𝜏2’s 
suggest inflation while the type I error rate for 𝛽 is controlled at the pre-specified 𝛼 
levels. This led us to examine the between-study variances more closely. 
 
Table F.1 Type I error rates for univariate score test  
Type I error 𝐻0: 𝛽 = 0 𝐻0: 𝜏1
2 = 0 𝐻0: 𝜏2
2 = 0 
𝛼 = 0.05 0.0481 0.0565 0.0537 
𝛼 = 0.01 0.0099 0.0354 0.0352 
 
 
F.2 Empirical Information Matrix vs. Correlation of Score Functions 
We wondered if the expected information matrix was correctly calculated. We simulated 
data as described in the simulation study and calculated score functions and the 
information matrix under the null hypothesis. We also computed the covariance matrix 
using the simulated score functions and compared to the average of the simulated 
information matrix under the null. We observed similar values for the two matrices 
(Table F.2) and concluded that the information matrix did not cause the inflation in 
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calculating the score test statistics. The matrices were calculated using 10,000 null 
simulations with 50 studies and dichotomous covariates. 
 
Table F.2 Average of simulated information matrix and computed covariance matrix 
using score functions 
Average of simulated 𝑰(𝜽0) Covariance of simulated score functions 
𝑰(𝜽0) = [
181 0 0
0 4258 1015
0 1015 5295
] 𝐶𝑜𝑣(𝑼(𝜽0)) = [
182 8 37
8 4211 1099
37 1099 5308
] 
 
 
F.3 Forest Plot 
We first plotted the scatterplot of score statistics (N=50, continuous covariates) versus 
LRT values (from chapter 3) computed using the same data. In Figure F.1, the top panel 
shows all Score-LRT pairs and the bottom panel shows the data points only between 
LRT=9 and LRT=11. Red triangles indicate extreme score statistics where the ratio of 
score values to LRT are greater than 4. We took three examples of extreme score and 
non-extreme score values with similar LRT from the bottom panel and explored in forest 
plots (Figure F.2a-c). In the forest plots, we wanted to examine if there were any 
possible influential points (in red rectangular box) that might cause inflation in 
computing test statistics and p-values. Those points had 95% confidence intervals that did 
not contain zero and had relatively large effect sizes compared to small variances. 
Because these points were simulated under the null, we expected that effect sizes with 
132 
  
 
small variances were close to zero or the 95% confidence intervals included zero. If the 
variance was not small and the 95% confidence did not include zero, the inflation in score 
statistics did not occur (See Figure F.2b, Non-Extreme Score for study 43 in blue oval 
box). We computed score statistics with and without the influential points and showed 
that those points caused inflated score statistics in Table F.3.  
 
Table F.3 Score test statistics (𝑇𝑠) computed including and excluding the influential 
points 
 Influential Points 
 Included Excluded 
𝑇𝑠 for Case 1 63.96 1.22 
𝑇𝑠 for Case 2 54.49 0.53 
𝑇𝑠 for Case 3 51.79 2.97 
 
 
Since we identified the issue with inflated score statistics, we have tested several 
approaches to obtain controlled type I error rates.   Re-calibration of the null distribution 
by estimating scaled-/shifted-parameters as we did in chapter 3 did not control type I 
error rates for the score test. Another approach was to add a small value to the error 
variances in order to avoid getting small variances and to stabilize the variances. We 
determined small values by the minimum variance divided by 2, 5, 10 or 20 for each 
simulation. However, this approach did not yield a uniform distribution in the histograms 
or follow the diagonal line in the Quantile-Quantile (Q-Q) plots as we expected (See 
Figure F.3). Lastly, we computed null score statistics (N=50) and constructed an 
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empirical null distribution by aggregating the null score values from all of the 
simulations. We computed p-values from the empirical null distribution. As shown in 
Figure F.4, we obtained well-controlled type I error rates using the empirical null 
distribution. A detailed description of the construction of the empirical null distribution is 
described in chapter 4. 
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Figure F.1 Scatter plot of score statistics vs. LRT  
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Figure F.2a Forest plots for extreme and non-extreme score statistics; Extreme 𝑇𝑠 = 64 and Non-Extreme 𝑇𝑠 = 12 
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Figure F.2b Forest plots for extreme and non-extreme score statistics; Extreme 𝑇𝑠 = 54 and Non-Extreme 𝑇𝑠 = 11 
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Figure F.2c Forest plots for extreme and non-extreme score statistics; Extreme 𝑇𝑠 = 52 and Non-Extreme 𝑇𝑠 = 11 
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Figure F.3 Histogram and Quantile-Quantile (Q-Q) plots for score test p-values adding small variances  
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Figure F.4 Histogram and Quantile-Quantile (Q-Q) plots for score test p-values calculated from the empirical null distribution 
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